<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006060</article-id><article-id pub-id-type="pmc">PMC11859979</article-id><article-id pub-id-type="doi">10.3390/ph18020247</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00247</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of Polyphenols in Dermatological Diseases: Exploring Pharmacotherapeutic Mechanisms and Clinical Implications</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4211-528X</contrib-id><name><surname>Salazar</surname><given-names>Juan</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7180-4765</contrib-id><name><surname>Ortega</surname><given-names>&#x000c1;ngel</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0914-5858</contrib-id><name><surname>P&#x000e9;rez</surname><given-names>Jos&#x000e9; Luis</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5522-7697</contrib-id><name><surname>Garrido</surname><given-names>Bermary</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0761-5879</contrib-id><name><surname>Santeliz</surname><given-names>Raquel</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0765-2290</contrib-id><name><surname>Galb&#x000e1;n</surname><given-names>N&#x000e9;stor</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6295-0229</contrib-id><name><surname>D&#x000ed;az</surname><given-names>Maria Paula</given-names></name><xref rid="af1-pharmaceuticals-18-00247" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3692-9917</contrib-id><name><surname>Cano</surname><given-names>Raquel</given-names></name><xref rid="af2-pharmaceuticals-18-00247" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2874-5330</contrib-id><name><surname>Cano</surname><given-names>Gabriel</given-names></name><xref rid="af3-pharmaceuticals-18-00247" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5179-5400</contrib-id><name><surname>Contreras-Velasquez</surname><given-names>Julio Cesar</given-names></name><xref rid="af4-pharmaceuticals-18-00247" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5208-9401</contrib-id><name><surname>Chac&#x000ed;n</surname><given-names>Maricarmen</given-names></name><xref rid="af5-pharmaceuticals-18-00247" ref-type="aff">5</xref><xref rid="c1-pharmaceuticals-18-00247" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Valdes</surname><given-names>Miguel</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Calzada</surname><given-names>Fernando</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00247"><label>1</label>Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela; <email>juanjsv18@hotmail.com</email> (J.S.); <email>angelort94@hotmail.com</email> (&#x000c1;.O.); <email>joseluispv2811@gmail.com</email> (J.L.P.); <email>bermarygarrido@gmail.com</email> (B.G.); <email>gabrielasanteliz29@gmail.com</email> (R.S.); <email>nestorag17@gmail.com</email> (N.G.); <email>mariadiazalbornoz@hotmail.com</email> (M.P.D.)</aff><aff id="af2-pharmaceuticals-18-00247"><label>2</label>Cl&#x000ed;nica General del Norte, Grupo de Estudio e Investigaci&#x000f3;n en Salud, Barranquilla 080002, Colombia; <email>raquelamiracano@gmail.com</email></aff><aff id="af3-pharmaceuticals-18-00247"><label>3</label>Institut f&#x000fc;r Pharmazie K&#x000f6;nigin-Luise, Freie Universit&#x000e4;t Berlin, Strasse 2-4, 14195 Berlin, Germany; <email>gabriel.simon.cano@fu-berlin.de</email></aff><aff id="af4-pharmaceuticals-18-00247"><label>4</label>Departamento de Productividad e Innovaci&#x000f3;n, Universidad de la Costa, Barranquilla 080002, Colombia; <email>jcontrer30@cuc.edu.co</email></aff><aff id="af5-pharmaceuticals-18-00247"><label>5</label>Centro de Investigaciones en Ciencias de la Vida (CICV), Facultad de Ciencias de la Salud, Universidad Sim&#x000f3;n Bol&#x000ed;var, Barranquilla 080002, Colombia</aff><author-notes><corresp id="c1-pharmaceuticals-18-00247"><label>*</label>Correspondence: <email>maricarmen.chacing@unisimon.edu.co</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>247</elocation-id><history><date date-type="received"><day>13</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Although not frequently lethal, dermatological diseases represent a common cause of consultation worldwide. Due to the natural and non-invasive approach of phytotherapy, research for novel alternatives, such as polyphenols, to treat skin disorders is a subject of interest in modern medicine. Polyphenols, in particular, have been considered because of their anti-inflammatory, antitumoral, antimicrobial, and antioxidant properties, low molecular weight, and lipophilic nature that enables the passage of these compounds through the skin barrier. This review discusses the treatment of common dermatological diseases such as acne vulgaris, fungal infections, dermatitis, alopecia, and skin cancer, using polyphenols as therapeutic and prophylactic options. The specific molecules considered for each disorder, mechanisms of action, current clinical trials, and proposed applications are also reviewed.</p></abstract><kwd-group><kwd>skin disorders</kwd><kwd>polyphenols</kwd><kwd>phytotherapy</kwd></kwd-group><funding-group><award-group><funding-source>Universidad Sim&#x000f3;n Bol&#x000ed;var, Vicerrector&#x000ed;a de Investigaci&#x000f3;n, Extensi&#x000f3;n e Innovaci&#x000f3;n, Internal funds for Research Strengthening, Barranquilla, Colombia</funding-source></award-group><funding-statement>This research was funded by Universidad Sim&#x000f3;n Bol&#x000ed;var, Vicerrector&#x000ed;a de Investigaci&#x000f3;n, Extensi&#x000f3;n e Innovaci&#x000f3;n, Internal funds for Research Strengthening, Barranquilla, Colombia.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00247"><title>1. Introduction</title><p>For decades, dermatologic diseases have occupied relevant positions as main complaints for medical consultation, cataloged by the Global Burden of Disease (GBD) study as the fourth main cause of non-lethal disease and the eighteenth main cause of disability worldwide [<xref rid="B1-pharmaceuticals-18-00247" ref-type="bibr">1</xref>]. These relevant facts transform these entities into important health issues, affecting all age groups and geographical areas [<xref rid="B2-pharmaceuticals-18-00247" ref-type="bibr">2</xref>].</p><p>Due to the prevalence and the socioeconomic burden generated by dermatologic diseases, it is imperative to find new therapeutic alternatives to diminish the consequences of these disorders [<xref rid="B3-pharmaceuticals-18-00247" ref-type="bibr">3</xref>]. For the past years, the study of natural polyphenols and their application in dermatologic diseases has obtained a primary interest. This group of molecules is widely distributed in the environment as secondary metabolites from plant sources, characterized by one or more phenolic rings within its chemical structure. Moreover, these molecules have demonstrated notable antioxidant, anti-inflammatory, antimicrobial, and in vivo as well as in vitro anticarcinogenic activities [<xref rid="B4-pharmaceuticals-18-00247" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-18-00247" ref-type="bibr">5</xref>].</p><p>Likewise, due to their low molecular weight and lipophilic properties similar to the stratum corneum, the cosmetic applications of these compounds have been explored, and topical extracts have been prepared, in order to obtain benefits from the direct effect of phenolic compounds when they penetrate the skin&#x000b4;s natural barrier; therefore, these compounds could represent a potential strategy for the prevention and treatment of frequent skin disorders [<xref rid="B6-pharmaceuticals-18-00247" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00247" ref-type="bibr">7</xref>]. Thus, this review summarizes current preclinical and clinical evidence of polyphenol-based phytochemicals as a treatment for skin disorders (SDs) and the potential molecular mechanisms involved.</p></sec><sec id="sec2-pharmaceuticals-18-00247"><title>2. Pharmacotherapeutic Mechanisms of Polyphenols in Main Skin Diseases</title><sec id="sec2dot1-pharmaceuticals-18-00247"><title>2.1. Acne Vulgaris (AV)</title><p>AV is considered one of the most common chronic dermatologic disorders in the teenage population. This pathology is characterized by its multifactorial etiology, mainly triggered by the proliferation of resident skin bacteria, such as <italic toggle="yes">Propionibacterium acne</italic> and excessive sebum production induced by androgens [<xref rid="B8-pharmaceuticals-18-00247" ref-type="bibr">8</xref>]. In addition, other events, such as the activation of inflammatory cascades leading to hyperkeratinization, increased reactive oxygen species (ROS), and reduced antioxidant activity, provoke hair follicle obstruction, resulting in comedo formation [<xref rid="B9-pharmaceuticals-18-00247" ref-type="bibr">9</xref>]. It is worth mentioning that the high costs and antibiotic resistance observed with conventional treatments have led to the study of numerous plant supplements, which have polyphenols, as an effective therapeutic alternative [<xref rid="B10-pharmaceuticals-18-00247" ref-type="bibr">10</xref>].</p><p>In this sense, an anti-inflammatory mechanism of the wild bitter gourd (<italic toggle="yes">Momordica charantia</italic>) total phenolic content leaf extract (TPCLE) has been studied due to its different polyphenolic compounds, such as phenolic acids, myricetin, quercetin, and luteolin as well as its acne-related properties. Clinical evidence indicates that the inhibition of growth of pathogens such as <italic toggle="yes">Propionibacterium acne</italic> is a potential therapeutic target to consider. In consequence, Huang et al. [<xref rid="B11-pharmaceuticals-18-00247" ref-type="bibr">11</xref>] tried to demonstrate this fact through intradermal injections of <italic toggle="yes">Propionibacterium acne</italic>, followed by TPCLE both in vivo and in vitro. TPCLE positively managed to attenuate the secretion of IL-8, IL-1&#x003b2;, and TNF&#x003b1; after inhibiting the expression of the Mitogen-Activated Protein Kinase (MAPK) and, subsequently, the Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells (NF-kB). Moreover, TPCLE inhibited Matrix Metalloproteinase-9 (MPP-9), an enzyme involved in extracellular matrix degradation and thus in acne lesions, demonstrating the great anti-inflammatory properties of this group of polyphenols [<xref rid="B11-pharmaceuticals-18-00247" ref-type="bibr">11</xref>].</p><p>A similar mechanism was found in oregano extracts, <italic toggle="yes">Origanum vulgare</italic> [<xref rid="B12-pharmaceuticals-18-00247" ref-type="bibr">12</xref>], widely distributed in rosmarinic acid, quercetin, carvacrol, and apigenin. In the said mechanism, the inactivation of transcriptional marker signaling responsible for the inhibition of NF-kB was attributed to the inactivation of Toll-Like receptor 2 (TLR2) [<xref rid="B12-pharmaceuticals-18-00247" ref-type="bibr">12</xref>]. Furthermore, the mRNA expression of NOS, ICAM-1, NF-kB, COX-2, and COX-1 [<xref rid="B13-pharmaceuticals-18-00247" ref-type="bibr">13</xref>] was inhibited in human keratinocytes NCTC 2544 with an <italic toggle="yes">M. styphelioides</italic> leaf extract treatment, rich in quercetin, gallic acid, and ellagic acid [<xref rid="B14-pharmaceuticals-18-00247" ref-type="bibr">14</xref>].</p><p>Additionally, a flavonoid widely distributed in apples and strawberries, known as phloretin, has been studied for its anti-inflammatory properties and potential antibacterial mechanism. Similarly, phloretin, found in its free form or glycosylated, inhibited the heterodimerization of TLR2/1; however, it also diminished the phosphorylation of the c-Jun N-terminal kinase (JNK) pathway in <italic toggle="yes">HaCaT</italic> keratinocytes stimulated by <italic toggle="yes">P. acnes</italic> in a dose-dependent manner. On the other hand, it was shown that the active site of the 3-ketoacyl-ACP synthase (KAS-III) interacted with rings A and B of the phloretin structure, blocking the reaction between <italic toggle="yes">P. acnes</italic>, KAS-III, and its substrates, and in consequence inhibiting fatty acid synthesis necessary for bacterial survival [<xref rid="B10-pharmaceuticals-18-00247" ref-type="bibr">10</xref>], therefore, proving the anti-inflammatory effect and great antibacterial potential of certain polyphenols.</p><p>In contrast, other studies on <italic toggle="yes">Quercus mongolica</italic> leaf extract (QML) examined the antioxidant activity of flavonoids, tannins, triterpenoids, and phenols, mainly pedunculagin (PD), and a decrease in IL-6 and IL-8 production as well as reduced concentrations of Nitric Acid (NA) were observed in the said studies. These phenomena are caused by diminished TLR-4 mRNA. This effect was also demonstrated in a study performed by Kim et al. [<xref rid="B15-pharmaceuticals-18-00247" ref-type="bibr">15</xref>], in which polyphenols of punicalagin, ellagic acid, and pomegranate peels (PPs) were used [<xref rid="B16-pharmaceuticals-18-00247" ref-type="bibr">16</xref>].</p><p>Finally, an enzyme regulatory mechanism involved in androgen metabolism has been studied for its role in the pathogenesis of acne. The 5&#x003b1;-reductase type 1 (5&#x003b1;AR-1) is an enzyme directly implicated in androgen-dependent sebum production and a presumptive therapeutic target. For this reason, Koseki et al. [<xref rid="B17-pharmaceuticals-18-00247" ref-type="bibr">17</xref>] attempted to explain the relationship between polyphenols and 5-AR in both in vivo and in vitro studies, using <italic toggle="yes">Bokusoku</italic> (BK), an extract of <italic toggle="yes">Quercus</italic> cortex, extensively found in gallate polyphenols, such as gallotannin and ellagitannin. In this sense, the inhibition of 5AR-1 and, thus, its implication in sebum production suppression were evidenced. Likewise, BK and one of its strongest phenolic compounds, the <italic toggle="yes">Pentagalloylglucose</italic>, suppressed testosterone-induced lipogenesis, blocking androgen-dependent cellular activity. Therefore, the inhibitory activity of 5&#x003b1;AR-1 and lipogenesis suppression are important therapeutic targets that might reduce sebum production in patients with acne [<xref rid="B17-pharmaceuticals-18-00247" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00247" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot2-pharmaceuticals-18-00247"><title>2.2. Dermatitis</title><p>Atopic dermatitis (AD) is a chronic inflammatory disease with a notable allergic component, which can appear from early childhood and is prone to recurrences. This pathology is characterized by clinical manifestations such as erythematous, itchy, and lichenified skin [<xref rid="B19-pharmaceuticals-18-00247" ref-type="bibr">19</xref>]. Its pathophysiology is initiated with an altered genotype, leading to intense immunity and hypersensitivity dysregulations mediated by the increased levels of Th2 and IgE [<xref rid="B20-pharmaceuticals-18-00247" ref-type="bibr">20</xref>]; furthermore, certain environmental and psychological triggers exacerbate AD development [<xref rid="B21-pharmaceuticals-18-00247" ref-type="bibr">21</xref>]. Likewise, intestinal dysbiosis has been implicated as an underlying mechanism of AD since the microbiota shapes immune responses systematically, thus alluding to the complex and multifactorial pathophysiology that comprises this disease [<xref rid="B22-pharmaceuticals-18-00247" ref-type="bibr">22</xref>].</p><p>As a consequence of AD recurrence, the chronic use of conventional anti-inflammatory therapy such as topical corticosteroids (TCSs) or calcineurin inhibitors (CIs) are not the safest options due to their known side effects. Moreover, the high economic burden, significant morbidity, and poor quality of life demand new therapeutic alternatives with minimum side effects [<xref rid="B23-pharmaceuticals-18-00247" ref-type="bibr">23</xref>]. Based on polyphenol influence through various anti-AD mechanisms, different polyphenolic compounds studied in preclinical trials promise to be innovative options for this disease.</p><p>Furthermore, the pro-inflammatory environment generated by increased cytokine levels has been considered a potential therapeutic target. In light of this, preclinical evidence has shown that diosmetin [<xref rid="B24-pharmaceuticals-18-00247" ref-type="bibr">24</xref>], quercetin, and galanin [<xref rid="B25-pharmaceuticals-18-00247" ref-type="bibr">25</xref>] drive a fall in pro-inflammatory cytokines such as IL-4, TNF&#x003b1;, and IL-1&#x003b2; expression via ERK, p38, and JNK, as well as NF-kB translocation inhibition. In addition, other flavonoids, like taxifolin, aromadendrin, padmatin, and chamaejasmine, have been linked to IgE reduction [<xref rid="B26-pharmaceuticals-18-00247" ref-type="bibr">26</xref>], as well as secondary metabolites of plant polyphenols such as 3-aryl isocoumarins and diarylheptanoids, and these compounds have shown modulatory activities on inflammatory pathways such as the inhibition of NF-kB activation [<xref rid="B21-pharmaceuticals-18-00247" ref-type="bibr">21</xref>,<xref rid="B27-pharmaceuticals-18-00247" ref-type="bibr">27</xref>]. Thus, their efficacy in inhibiting pleiotropic cytokines of Th2 cells that regulate isotype changes from different immunoglobulins to IgE makes these flavonoids an alternative to treat inflammatory responses associated with AD.</p><p>Recently, another mechanism to attenuate the pruritus caused by AD has been studied. Nevertheless, the pathophysiological mechanism of AD pruritus is still unknown. Studies show that Thymic Stromal Lymphopoietin (TSLP) is directly linked to pruritus and severeness of AD. Consequently, Fitoussi et al. [<xref rid="B28-pharmaceuticals-18-00247" ref-type="bibr">28</xref>] studied the efficacy of <italic toggle="yes">Tambourissa trichophylla</italic> leaf extract (TTLE), with a titration of &#x0003e;40% polyphenols, mainly troxerutin. Inhibition of TSLP secretion was observed, and the said effect was associated with the IL-1&#x003b1; pathway, a cytokine able to induce the expression of TSLP and therefore alter the cutaneous barrier [<xref rid="B29-pharmaceuticals-18-00247" ref-type="bibr">29</xref>]. Likewise, treatment with systemic resveratrol was associated with diminished TSLP expression in skin lesions similar to EA. Therefore, phenolic compounds seem to be potential therapeutic tools to alleviate AD symptoms such as pruritus.</p><p>On the other hand, AD has a close relationship to the intestinal microbiota. Interestingly, AD patients present imbalances between <italic toggle="yes">Clostridium</italic> spp. and beneficial bacteria such as <italic toggle="yes">Bifidobacterium</italic> spp. [<xref rid="B30-pharmaceuticals-18-00247" ref-type="bibr">30</xref>]. In this context, the acacia polyphenol (AP) has been studied, and the topical application of this molecule produced pruritus reduction in DA lesions after inhibiting skin inflammation, and, in consequence, creating a systemic influence in the gut&#x02013;skin axis. This fact has been demonstrated due to increased beneficial bacteria, such as <italic toggle="yes">Bifidobacterium</italic> spp. and <italic toggle="yes">Lactobacillus</italic> spp., after AP use in murine models with AD [<xref rid="B30-pharmaceuticals-18-00247" ref-type="bibr">30</xref>]. Moreover, a similar behavior was observed after the utilization of <italic toggle="yes">Schizonepeta tenuifolia</italic> Briquet (STB) and <italic toggle="yes">Alpinia oxyphylla</italic> Miquel (AOM) extracts, which are rich in flavonoids and gallic acid, and the said compounds induced changes in the microbiome and therefore supported the importance of the gut&#x02013;skin axis theory [<xref rid="B31-pharmaceuticals-18-00247" ref-type="bibr">31</xref>].</p><p>It is important to point out that, currently, only a few preclinical trials focus on the effects of phenolic compounds in contact dermatitis (CD). Contact dermatitis is characterized by extreme hypersensitivity to allergens once they reach the skin. Thus, Jegal et al. [<xref rid="B32-pharmaceuticals-18-00247" ref-type="bibr">32</xref>] employed <italic toggle="yes">Wikstroemia indica</italic> extract, rich in flavonoids, lignans, and coumarins, to assess their efficacy on CD. Quercetin was strongly associated with the suppression of lysosomal enzyme &#x003b2;-hexosaminidase and IL-4 mRNA expression, which are important regulators of immune responses during the initial phase of CD. Even though more preclinical studies are needed in this field, the potential use of polyphenols as a new therapeutic tool for treating CD and AD is highly relevant.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00247"><title>2.3. Skin Fungal Infections</title><p>Dermatomycosis comprises a wide range of diseases that target skin, nails, and hair [<xref rid="B33-pharmaceuticals-18-00247" ref-type="bibr">33</xref>]. These are considered the most frequent mycotic infections worldwide and are caused by different etiological agents such as (i) dermatophytes, including the genre <italic toggle="yes">Trichophyton</italic>, <italic toggle="yes">Microsporum</italic>, and <italic toggle="yes">Epidermophyton</italic>, responsible for dermatophytosis and onychomycosis, as well as (ii) yeasts responsible for cutaneous candidiasis and pityriasis versicolor, such as <italic toggle="yes">Candida</italic> spp. and <italic toggle="yes">Malassezia</italic> spp., respectively [<xref rid="B34-pharmaceuticals-18-00247" ref-type="bibr">34</xref>]. A common feature among fungal pathogens of the skin is the production of keratinolytic enzymes responsible for the degradation of the keratinized epithelium and induction of inflammatory responses in the site of infection [<xref rid="B35-pharmaceuticals-18-00247" ref-type="bibr">35</xref>]. The aforementioned process depends on the intensity of inflammatory mediators produced by the strains involved and the host&#x02019;s response to the pathogen [<xref rid="B36-pharmaceuticals-18-00247" ref-type="bibr">36</xref>].</p><p>In this context, an effective approach to treat dermatomycosis involves adding topical corticosteroids to an antimycotic therapy to diminish initial inflammatory symptoms and avoid bacterial superinfection. However, the risk of side effects and its high cost are difficulties worth considering [<xref rid="B37-pharmaceuticals-18-00247" ref-type="bibr">37</xref>]. Recently, different phenolic compounds have been proposed as an alternative to this scenario since these molecules can interfere directly with the growth and survival of the fungal species, attenuate inflammatory responses, and regulate ROS production (<xref rid="pharmaceuticals-18-00247-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B37-pharmaceuticals-18-00247" ref-type="bibr">37</xref>].</p><p>The effect of polyphenols on fungal growth occurs through various cellular targets. The inhibition of ergosterol biosynthesis has been documented as one of the mechanisms, considering that this blockade constitutes a key factor that leads to alterations in the plasmatic membrane and a consequent loss of cellular integrity [<xref rid="B38-pharmaceuticals-18-00247" ref-type="bibr">38</xref>]. Along with this perspective, it has been demonstrated that gallic acid (GA) [<xref rid="B39-pharmaceuticals-18-00247" ref-type="bibr">39</xref>] and ellagic acid (EA) [<xref rid="B39-pharmaceuticals-18-00247" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-18-00247" ref-type="bibr">40</xref>] significantly diminish the ergosterol content in the membrane of <italic toggle="yes">T. rubrum</italic> in vitro by reducing the activity of limiting enzymes of sterol synthesis: sterol 14&#x003b1;-demethylase P450 (CYP51) and squalene epoxidase (SE). This potential antifungal activity of both compounds is equivalent to conventional treatments such as fluconazole and terbinafine.</p><p>Similarly, caffeic acid (CA) and Licochalcone A (LicoA) exhibit a powerful antimycotic effect on <italic toggle="yes">T. rubrum</italic>, with a minimum inhibitory concentration (MIC) of 86.59 and 11.52 &#x003bc;M, respectively. The mechanism involved encompasses an inhibition of gene expression related to ergosterol biosynthesis, plasmatic membrane synthesis, and glyoxylate cycle, with the latter process significantly increased with LicoA, suggesting a multimodal role of these agents, which act by interfering with key pathways of <italic toggle="yes">T. rubrum</italic> survival [<xref rid="B41-pharmaceuticals-18-00247" ref-type="bibr">41</xref>]. An additional therapeutic goal to consider is the fatty acid synthase (FAS), whose inhibition reduces fatty acid synthesis and, consequently, alters the mycotic membrane lipidic content [<xref rid="B42-pharmaceuticals-18-00247" ref-type="bibr">42</xref>]. In this sense, the antifungal action of flavonoids, such as gallate of epigallocatechin [<xref rid="B43-pharmaceuticals-18-00247" ref-type="bibr">43</xref>], quercetin, and trans-chalcone [<xref rid="B44-pharmaceuticals-18-00247" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceuticals-18-00247" ref-type="bibr">45</xref>] via FAS blockade, has been reported.</p><p>In addition to the effect on fatty acid metabolism, the action of trans-chalcone over different virulence factors produced by <italic toggle="yes">T. rubrum</italic> has been described. In line with this, the downregulation of genes that codify proteases and heat shock proteins (Hsp70, Hdp88, and Hsp90) has been observed. Likewise, this flavonoid can interact with MAPK, Tor, and CDK signaling pathways, which mediate the assembly and maintenance of the plasmatic membrane. These findings suggest a role for the aforementioned compound in several aspects of dermatophyte biology that should be further explored in future investigations [<xref rid="B46-pharmaceuticals-18-00247" ref-type="bibr">46</xref>]. In contrast, Gaziano et al. assessed in silico and in vitro anti-dermatophytic effects of phenolic compounds extracted from <italic toggle="yes">Cardiospermum halicacabum.</italic> Evidence indicated that rutin and luteolin directly affect the growth of <italic toggle="yes">T. rubrum</italic>, in a potential mechanism mediated through the interaction with the ATP domain of <italic toggle="yes">Hsp90</italic>. Interestingly, although both compounds showed a particular effect, it was not superior to the effect demonstrated by the total leaf extract. Thus, it can be inferred that using <italic toggle="yes">Cardiospermum halicacabum</italic> extract could represent a new antifungal strategy to explore as a single agent or in combination with conventional drugs [<xref rid="B47-pharmaceuticals-18-00247" ref-type="bibr">47</xref>].</p><p>On the other hand, baicalein and wogonin, two flavones present in root extracts of <italic toggle="yes">Scutellaria baicalensis</italic>, exert a potential antifungal activity against <italic toggle="yes">T. rubrum</italic>, <italic toggle="yes">T. mentagrophytes</italic>, <italic toggle="yes">A. fumigatus</italic>, and <italic toggle="yes">C. albicans</italic>. Moreover, the powerful effect of baicalein against the previously mentioned pathogens has been observed; meanwhile, wogonin inhibited the activity of every pathogen except <italic toggle="yes">C. albicans.</italic> The mechanism of action is associated with increments in mitochondrial ROS and, therefore, the induction of modifications in mitochondrial membrane potential (MMP), which results in cellular apoptosis [<xref rid="B48-pharmaceuticals-18-00247" ref-type="bibr">48</xref>]. Likewise, isoquercitrin (ISO) exerts a synergic effect with fluconazole and amphotericin B, promoting cellular apoptosis and altering the permeability of <italic toggle="yes">C. albicans</italic> membrane through the inhibition of Superoxide Dismutase (SOD) mitochondrial activity, leading to increments in oxidative stress levels [<xref rid="B49-pharmaceuticals-18-00247" ref-type="bibr">49</xref>].</p><p>Lastly, the anti-inflammatory potential of some phenolic compounds represents an attractive therapeutic target to explore in dermatomycosis. In this sense, Gomes et al. evaluated the anti-dermatophytic effect of <italic toggle="yes">Salacia senegalensis</italic> leaf extract, observing the antifungal activity of the plant against <italic toggle="yes">T. rubrum</italic> and <italic toggle="yes">E. floccosum</italic>, and these effects could be partially attributed to the presence of flavanols with potential synergic actions, such as quercetin, myricitrin, and quercitrin. Likewise, the anti-inflammatory effect of the extract stands out in a mechanism dependent on eicosanoid derivates of 5-lipooxygenase (5-LOX). Hence, studying flavonoids in <italic toggle="yes">Salacia senegalensis</italic> extract might represent an alternative to consider when it comes to reducing acute inflammatory responses associated with dermatophytes [<xref rid="B50-pharmaceuticals-18-00247" ref-type="bibr">50</xref>].</p></sec><sec id="sec2dot4-pharmaceuticals-18-00247"><title>2.4. Alopecia</title><p>The social stigma generated from hair loss (HL) has made this condition a common complaint in dermatologic appointments [<xref rid="B51-pharmaceuticals-18-00247" ref-type="bibr">51</xref>]. From a clinical perspective, alopecia possesses different etiologies. Androgenic alopecia (AGA) is the most frequent, affecting men and women through different stages of life, with elevated dihydrotestosterone (DHT) levels as its main contributing factor [<xref rid="B52-pharmaceuticals-18-00247" ref-type="bibr">52</xref>]. Furthermore, AGA is a non-scarring alopecia characterized by rounded, flat, alopecic patches and caused by the autoimmune destruction of the hair follicle (HF) [<xref rid="B53-pharmaceuticals-18-00247" ref-type="bibr">53</xref>]. Finally, telogen effluvium (TE) is a heterogeneous entity characterized by sudden and diffuse hair loss that occurs around three months after a triggering event, as a consequence of regular hair growth cycle alteration, abruptly transitioning from the anagen phase (active growth) to telogen phase (rest) [<xref rid="B54-pharmaceuticals-18-00247" ref-type="bibr">54</xref>].</p><p>Despite the growing interest in finding new therapeutic strategies to treat HL in recent years, the available pharmacological options are still scarce. The only drugs currently approved by the FDA to manage this condition are minoxidil and finasteride. In addition, due to limited efficacy and potential side effects, the use of these drugs remains controversial [<xref rid="B55-pharmaceuticals-18-00247" ref-type="bibr">55</xref>]. On the contrary, phenolic extracts have emerged as a safer and more economical alternative to treat HL. Significant effects of epigallocatechin [<xref rid="B56-pharmaceuticals-18-00247" ref-type="bibr">56</xref>], quercetin [<xref rid="B57-pharmaceuticals-18-00247" ref-type="bibr">57</xref>], and baicalein [<xref rid="B57-pharmaceuticals-18-00247" ref-type="bibr">57</xref>], among others, have been documented in diverse experimental models.</p><p>Several hypotheses have been developed to clarify the potential mechanisms of action of polyphenols to induce hair growth. An attractive target explored is the regulation of hair follicle dermal papilla cell (DPC) activities, a specialized cellular group that controls the proliferation and regeneration of hair follicles by producing different growth factors [<xref rid="B58-pharmaceuticals-18-00247" ref-type="bibr">58</xref>]. Studies indicate that hesperetin and naringenin perform important roles via the stimulation of human DPC proliferation in vitro as well as cellular protection from oxidative stress mediated by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and increments in VEGF, which is an important angiogenic factor, capable of promoting the restoration of oxygen supply within the growing HF [<xref rid="B59-pharmaceuticals-18-00247" ref-type="bibr">59</xref>].</p><p>Furthermore, baicalein exerts a promising role in the modulation of DPC activities. It has been documented that the topical application of this flavonoid promotes follicular growth in Balb/c-null mice through a potential Wnt/&#x003b2;-catenin pathway-dependent mechanism and alkaline phosphatase (ALP) activation in this cellular population [<xref rid="B60-pharmaceuticals-18-00247" ref-type="bibr">60</xref>]. Likewise, this mechanism has been demonstrated with other compounds and cell types. It has been observed that a glycoside extracted from the medicinal plant <italic toggle="yes">Cornus officinalis</italic> known as morroniside can stimulate the proliferation and migration of the outer root sheath cells (ORSCs), as well as induce HF growth in vitro through the Wnt/&#x003b2;-catenin signaling pathway in a dose-dependent manner. Thus, the regulation of this pathway constitutes a common mechanism used by phenolic extracts to induce the onset of anagen phase and follicular growth [<xref rid="B61-pharmaceuticals-18-00247" ref-type="bibr">61</xref>].</p><p>On the other hand, the prolongation of DPC viability represents a key approach to avoid the transition to telogen phase and, as a consequence, attenuate HL [<xref rid="B62-pharmaceuticals-18-00247" ref-type="bibr">62</xref>]. Accordingly, Shin et al. demonstrated that <italic toggle="yes">Polygonum multiflorum</italic> (PM) extract, whose main component is 2,3,5,4&#x02032;-tetrahydroxyestilbene-2-<italic toggle="yes">O</italic>-&#x003b2;-<sc>d</sc>-glucoside (TSG), induces an anti-apoptotic effect in human cultured DPCs through the regulation of Bcl-2/BAD, thus extending the anagen phase. Moreover, the extract promotes increments in the production of VEGF, PDGF, and EGF and inhibits the effect mediated by DHT on androgenic receptor (AR) expression. This multimodal mechanism of PM extract on hair growth might represent a potential approach to treating AGA; however, new studies to explore this phenomenon with individual intake of TSG are required [<xref rid="B63-pharmaceuticals-18-00247" ref-type="bibr">63</xref>].</p><p>Lastly, fisetin and resveratrol have played a key role in the transition from the telogen to anagen phase and, consequently, in dorsal skin hair growth in mice. In a mechanism involving the telomerase reverse transcriptase, whose overexpression induced &#x003b2;-catenin nuclear translocation, increments in cytokines such as insulin growth factor-1 (IGF-1) and keratinocyte growth factor (KGF), as well as the promotion of stem cell proliferation within the hair follicle, were observed. Therefore, this positive effect of TERT on the anagen phase, induced by these polyphenols, represents a therapeutic mechanism to consider in future investigations [<xref rid="B64-pharmaceuticals-18-00247" ref-type="bibr">64</xref>].</p></sec><sec id="sec2dot5-pharmaceuticals-18-00247"><title>2.5. Skin Cancer</title><p>Skin cancer is one of the most common cancers worldwide. The number of new cases has increased alarmingly over the last decade. This increase could be attributed to continuous exposure to sunlight and the ozone layer changes that predispose the earth&#x02019;s surface to higher ultraviolet (UV) radiation [<xref rid="B65-pharmaceuticals-18-00247" ref-type="bibr">65</xref>]. Skin cancer is classified into two subtypes: (i) Non-Melanoma Skin Cancer (NMSC), also known as keratinocyte cancer, which represents the most common malignant neoplasia, with Basal Cell Carcinoma (BCC) and squamous cell carcinoma (SCC) comprising 99% of every NMSC [<xref rid="B66-pharmaceuticals-18-00247" ref-type="bibr">66</xref>], and (ii) Melanoma Skin Cancer (MSC), even though it only represents 3% of all the skin cancer cases, it has the highest mortality rate and poorer prognosis [<xref rid="B67-pharmaceuticals-18-00247" ref-type="bibr">67</xref>].</p><p>The economic burden of skin cancer on the health system worldwide has also increased [<xref rid="B68-pharmaceuticals-18-00247" ref-type="bibr">68</xref>], boosting the research to find new, more economical and safer therapeutic strategies. In this context, it has been noted that polyphenols have significant effects on cancer progression through the modification of signaling cascades affected during carcinogenesis [<xref rid="B69-pharmaceuticals-18-00247" ref-type="bibr">69</xref>], proliferation, migration, and invasion [<xref rid="B70-pharmaceuticals-18-00247" ref-type="bibr">70</xref>], as well as angiogenesis [<xref rid="B69-pharmaceuticals-18-00247" ref-type="bibr">69</xref>], therefore improving patients&#x02019; prognosis.</p><p>UV rays can penetrate the epidermis and reach the superior dermis to induce biological side effects, including oxidative stress, inflammation, DNA damage, and premature photoaging [<xref rid="B71-pharmaceuticals-18-00247" ref-type="bibr">71</xref>]. DNA damage results in cyclobutane pyrimidine dimer (CPD) formation. These molecules act as promoters of immunosuppression and trigger photocarcinogenesis [<xref rid="B72-pharmaceuticals-18-00247" ref-type="bibr">72</xref>]. Furthermore, the potential of phenolic compounds extracted from pomegranate (<italic toggle="yes">Punica granatum</italic>), such as punicalagin and urolithin, as DNA repair tools has been documented. These molecules possess powerful properties as SIRT1 inducers, facilitating Nucleotide Excision Repair (NER) through the deacetylation of XPC and XPA genes, finally eliminating previously formed CPDs [<xref rid="B73-pharmaceuticals-18-00247" ref-type="bibr">73</xref>].</p><p>Currently, it is known that reactive oxygen species have a major role in cutaneous carcinogenesis via the overactivation of multiple pathways such as MAPK, phosphatidylinositol 3-kinase (PI3K)/kinase protein B (AKT)/mammalian target of rapamycin (mTOR), and NF-kB pathway [<xref rid="B74-pharmaceuticals-18-00247" ref-type="bibr">74</xref>]. Likewise, clinical evidence highlights the bioprotector effect of <italic toggle="yes">Arachis hypogaea</italic> (peanut) polyphenols, which include catechin, epicatechin, procyanidin, and quercetin, against oxidative stress due to their capacity to diminish ROS levels [<xref rid="B75-pharmaceuticals-18-00247" ref-type="bibr">75</xref>]. Moreover, Eskandari et al. monitored reactions between hydrogen peroxide, quercetin, resveratrol, and piceatannol on the skin through an oxygen electrode covered with a cutaneous membrane (SCOE) as a tool in vitro, demonstrating that these polyphenolic compounds promote antioxidant reactions in 2&#x02013;22 min [<xref rid="B76-pharmaceuticals-18-00247" ref-type="bibr">76</xref>].</p><p>In addition, polyphenols, such as resveratrol, have shown antiproliferative effects on tumor cells due to the downregulation of phosphorylated PI3K and AKT [<xref rid="B77-pharmaceuticals-18-00247" ref-type="bibr">77</xref>]. Similarly, epigenin, a natural flavonoid, has proven to inhibit skin cancer induced by UV rays via mTOR blockade, improving keratinocyte autophagy and diminishing its proliferation [<xref rid="B78-pharmaceuticals-18-00247" ref-type="bibr">78</xref>]. These antitumoral effects were observed in an in vitro and in vivo study performed by Chen et al., where tea polyphenols (TPs) showed time- and dose-dependent effects over melanoma cells, significantly inhibiting their proliferative, migrative, and invasive capacity through TLR4 suspension [<xref rid="B70-pharmaceuticals-18-00247" ref-type="bibr">70</xref>].</p><p>Polyphenols could contribute to skin cancer prevention and treatment through the induction of malignant cell apoptosis; as highlighted in Arumugam et al.&#x02019;s preclinical trial, the synergic use of polyphenols such as resveratrol, epigallocatechin-3-gallate, and diallyl trisulfide could play a significant role in apoptosis inhibition. In the said study, A431 cells were used in a human epidermoid carcinoma model, and the application of polyphenolic compounds induced apoptosis inhibition via Bax and Bad upregulation, as well as pre-apoptotic proteins, while molecules such as Bcl2 and caspases 3 and 9 were downregulated [<xref rid="B79-pharmaceuticals-18-00247" ref-type="bibr">79</xref>].</p></sec><sec id="sec2dot6-pharmaceuticals-18-00247"><title>2.6. Rosacea</title><p>Rosacea is a chronic inflammatory dermatosis affecting the central face, characterized by persistent erythema, telangiectasia, and papulopustular eruptions. Although its etiology is multifactorial, including genetic and environmental influences, the exact pathophysiological mechanisms remain elusive (<xref rid="pharmaceuticals-18-00247-f002" ref-type="fig">Figure 2</xref>).</p><p>Rosacea is a prevalent inflammatory skin condition predominantly affecting the central face, with symptoms that significantly deteriorate the patient&#x02019;s quality of life [<xref rid="B80-pharmaceuticals-18-00247" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceuticals-18-00247" ref-type="bibr">81</xref>]. It manifests primarily as facial flushing, erythema, telangiectasia, and papules/pustules. The pathogenesis of rosacea is complex and not fully understood, but it likely involves a combination of genetic predisposition and environmental triggers.</p><p>Rosacea presents in four distinct subtypes, each with unique clinical features: 1-Erythematotelangiectatic Rosacea (ETR) characterized by persistent facial redness, flushing, and visible blood vessels; 2-Papulopustular Rosacea (PPR) which features small, inflammatory papules and pustules on a backdrop of erythema; 3-Phymatous Rosacea involves skin thickening and irregular surface nodules, most often on the nose (rhinophyma); and 4-Ocular Rosacea that affects the eyes, leading to irritation, redness, and watery eyes [<xref rid="B82-pharmaceuticals-18-00247" ref-type="bibr">82</xref>].</p><p>The pathogenesis of rosacea is complex, including an overabundance of <italic toggle="yes">Demodex mites</italic>, particularly <italic toggle="yes">Demodex folliculorum</italic>, associated with triggering inflammatory reactions contributing to rosacea. Evidence suggests that rosacea patients exhibit abnormal immune responses, including increased levels of pro-inflammatory cytokines that contribute to skin inflammation and damage. Environmental triggers such as UV radiation, extreme temperatures, spicy foods, and alcohol have been recognized for exacerbating rosacea symptoms [<xref rid="B82-pharmaceuticals-18-00247" ref-type="bibr">82</xref>].</p><p>Emerging research suggests that antioxidants and polyphenols, which can neutralize free radicals and reduce oxidative stress, have potential clinical benefits in rosacea treatment. Polyphenols exert anti-inflammatory effects, potentially attenuating inflammatory pathways involved in rosacea. They also enhance the skin&#x02019;s barrier function, which helps protect against environmental irritants. Notable polyphenols with proven efficacy in rosacea management include green tea extract, which contains epigallocatechin gallate (EGCG), known for its strong anti-inflammatory and antioxidant effects. Resveratrol, found in grapes and berries, offers significant anti-inflammatory and antioxidant benefits, making it beneficial in reducing rosacea symptoms. Grape seed extract is known for its high proanthocyanidin content, which has anti-inflammatory and antioxidant capabilities [<xref rid="B83-pharmaceuticals-18-00247" ref-type="bibr">83</xref>].</p><p>Aside from polyphenols, rosacea management includes topical treatments such as metronidazole, azelaic acid, and ivermectin, which are widely used. Oral antibiotics like doxycycline and tetracycline are prescribed for more severe cases. Laser and light therapies target vascular and inflammatory components of rosacea, offering symptom improvement [<xref rid="B84-pharmaceuticals-18-00247" ref-type="bibr">84</xref>].</p><p>Rosacea is a complex dermatological condition that significantly impacts patients&#x02019; lives. While the exact cause of rosacea is still under investigation, integrating polyphenols into treatment regimens offers a promising approach due to their antioxidative and anti-inflammatory properties. Comprehensive management, incorporating established and emerging therapies tailored to individual patient needs, remains paramount for effectively controlling and improving rosacea symptoms.</p><p>Moreover, the role of polyphenols in dermatology, particularly in the context of inflammatory skin diseases like rosacea, extends beyond their antioxidative and anti-inflammatory properties. Polyphenols have been shown to inhibit the activation of NF-kB, a key transcription factor in the inflammatory response, which leads to the downregulation of various pro-inflammatory cytokines and mediators involved in rosacea [<xref rid="B85-pharmaceuticals-18-00247" ref-type="bibr">85</xref>]. Additionally, polyphenols can modulate the activity of enzymes such as cyclooxygenase and lipoxygenase, further reducing the synthesis of pro-inflammatory eicosanoids, i.e., lipid compounds that exacerbate inflammation. This multifaceted mechanism of action makes polyphenols an attractive component in the holistic management of rosacea, offering potential synergies with other therapeutic modalities to enhance treatment efficacy and patient outcomes [<xref rid="B85-pharmaceuticals-18-00247" ref-type="bibr">85</xref>].</p></sec><sec id="sec2dot7-pharmaceuticals-18-00247"><title>2.7. Melasma</title><p>Melasma, an acquired facial hyperpigmentation, predominantly affects women of darker skin and is characterized by symmetrical hyperpigmented patches typically found on the forehead, cheeks, upper lip, and chin, significantly impacting the quality of life [<xref rid="B85-pharmaceuticals-18-00247" ref-type="bibr">85</xref>,<xref rid="B86-pharmaceuticals-18-00247" ref-type="bibr">86</xref>]. These patches can cause emotional distress and affect social interactions, making a thorough understanding of the pathogenic mechanisms and therapeutic options crucial for effective management.</p><p>The etiology of melasma is considered multifactorial, involving genetic, hormonal, and environmental components. Genetic predisposition plays a significant role, with a strong concordance observed among twins and family members, and polymorphisms in genes related to melanogenesis, such as MC1R and ASIP, have been linked to an increased risk. Hormonally, estrogen and progesterone, which regulate melanogenesis, are crucial, with a higher prevalence of melasma noted during pregnancy, menopause, and among users of oral contraceptives or hormone therapy. Environmentally, UV radiation is a primary trigger, stimulating melanin production and exacerbating hyperpigmentation. Other factors like heat, stress, and certain medications also contribute to the onset or worsening of melasma [<xref rid="B87-pharmaceuticals-18-00247" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceuticals-18-00247" ref-type="bibr">88</xref>].</p><p>Several risk factors increase the likelihood of developing melasma, including female gender, darker skin phototypes, a family history of melasma, hormonal fluctuations during pregnancy or due to hormone therapy, and excessive UV radiation exposure [<xref rid="B88-pharmaceuticals-18-00247" ref-type="bibr">88</xref>].</p><p>Treatment of melasma should be tailored to each individual, considering the severity of the condition, the patient&#x02019;s skin phototype, and clinical characteristics. Commonly employed therapies include depigmenting agents like hydroquinone, azelaic acid, kojic acid, and arbutin, which are effective in lightening hyperpigmented patches. Strict photoprotection is crucial to prevent progression and relapses, with the daily use of broad-spectrum sunscreen being recommended. Laser procedures such as Q-switched lasers, Nd: YAG lasers, and intense pulsed light have shown efficacy for refractory cases. Often, combining depigmenting agents, photoprotection, and laser treatments yields the best results [<xref rid="B89-pharmaceuticals-18-00247" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceuticals-18-00247" ref-type="bibr">90</xref>].</p><p>Polyphenols have recently gained attention in melasma management. Their mechanisms include neutralizing free radicals to reduce oxidative stress contributing to melanogenesis, modulating inflammatory pathways to alleviate associated inflammation, and potentially inhibiting tyrosinase, a key enzyme in melanin production. While research into polyphenols&#x02019; effectiveness in melasma treatment is still developing, initial studies have shown promising results, suggesting that these compounds could significantly manage this complex condition [<xref rid="B91-pharmaceuticals-18-00247" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceuticals-18-00247" ref-type="bibr">92</xref>].</p></sec></sec><sec id="sec3-pharmaceuticals-18-00247"><title>3. Clinical Evidence of Polyphenols in Dermatological Diseases</title><p>During the last few years, numerous preclinical and clinical studies have highlighted the therapeutic benefits of polyphenols in dermatologic pathologies. These compounds&#x02019; mechanistic and pharmacological features indicate their possible influence in acne vulgaris, dermatitis, skin fungal infections, alopecia, and skin cancer pathophysiology [<xref rid="B23-pharmaceuticals-18-00247" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-18-00247" ref-type="bibr">24</xref>,<xref rid="B31-pharmaceuticals-18-00247" ref-type="bibr">31</xref>,<xref rid="B39-pharmaceuticals-18-00247" ref-type="bibr">39</xref>,<xref rid="B70-pharmaceuticals-18-00247" ref-type="bibr">70</xref>]. Thus, their potential clinical use has become an object of investigation. The following section summarizes key clinical evidence regarding polyphenols&#x02019; impact in treating multiple skin disorders (<xref rid="pharmaceuticals-18-00247-t001" ref-type="table">Table 1</xref>).</p><p>Firstly, green tea is the most extensively investigated polyphenol in acne vulgaris on a clinical level [<xref rid="B93-pharmaceuticals-18-00247" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceuticals-18-00247" ref-type="bibr">94</xref>,<xref rid="B100-pharmaceuticals-18-00247" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-18-00247" ref-type="bibr">101</xref>,<xref rid="B102-pharmaceuticals-18-00247" ref-type="bibr">102</xref>,<xref rid="B103-pharmaceuticals-18-00247" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceuticals-18-00247" ref-type="bibr">104</xref>,<xref rid="B105-pharmaceuticals-18-00247" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceuticals-18-00247" ref-type="bibr">106</xref>]. In this sense, Kim et al. [<xref rid="B93-pharmaceuticals-18-00247" ref-type="bibr">93</xref>], in a meta-analysis of five randomized controlled studies, reported that the topical application of green tea extract is favorable for acne treatment without significant side effects. Its topical use significantly diminished the cases of inflammatory lesions (&#x02212;9.38; IC 95%: &#x02212;14.13 &#x02212;4.63), the number of inflammatory lesions (&#x02212;11.39; IC del 95%: &#x02212;15.91 &#x02212;6.86), and non-inflammatory lesions (&#x02212;32.44; IC del 95%: &#x02212;39.27 &#x02212;25.62).</p><p>Likewise, in a randomized, double-blind, and placebo-controlled trial [<xref rid="B106-pharmaceuticals-18-00247" ref-type="bibr">106</xref>], significant reductions in acne lesions located in the nose, perioral area, and chin were reported after the use of a daily dose of 856 mg of epigallocatechin gallate in women with post-puberty acne. Similarly, Yoon et al. [<xref rid="B105-pharmaceuticals-18-00247" ref-type="bibr">105</xref>] conducted an 8-week randomized, double-blinded, split-face clinical trial, where 1% and 5% epigallocatechin-3-gallate solutions significantly improved inflammatory and non-inflammatory acne lesions. Moreover, Junt et al. [<xref rid="B104-pharmaceuticals-18-00247" ref-type="bibr">104</xref>] reported in a clinical study the significant symptomatic improvement in patients with acne, with reductions in comedones (61%) and blisters (28%) after topical treatment with green tea catechin (polyphenol: 60, 20 mg/mL).</p><p>The clinical use of other polyphenols to treat acne vulgaris has also been tested [<xref rid="B94-pharmaceuticals-18-00247" ref-type="bibr">94</xref>,<xref rid="B100-pharmaceuticals-18-00247" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-18-00247" ref-type="bibr">101</xref>,<xref rid="B107-pharmaceuticals-18-00247" ref-type="bibr">107</xref>]. Waranuch et al. [<xref rid="B94-pharmaceuticals-18-00247" ref-type="bibr">94</xref>], in a single-center, parallel, randomized controlled trial, assessed the anti-acne and anti-blemish properties of a hydrogel formulated with a combination of <italic toggle="yes">Aloe barbadensis</italic> leaf extract, <italic toggle="yes">Garcinia mangostana</italic> peel extract, and <italic toggle="yes">Camellia sinensis</italic> leaf extract. A significant reduction in total acne lesions, severeness index, skin redness, and mean melanin value was reported. Furthermore, in a single-blinded, placebo-controlled, split-face comparative study [<xref rid="B107-pharmaceuticals-18-00247" ref-type="bibr">107</xref>], a considerable reduction in sebum secretions was reported after using green tea lotus extract emulsion.</p><p>On the other hand, their potential clinical use in alopecia has gained interest in the last few years. In a randomized controlled placebo study, <italic toggle="yes">Trifolium pratense</italic> flower extract and a biomimetic peptide were applied to thirty patients with mild-to-moderate active HL for four months [<xref rid="B96-pharmaceuticals-18-00247" ref-type="bibr">96</xref>]. A significant increase (46%) in the treated group was found between the anagen/telogen (A/T) relationship. The anagen hair increased by +13%, and telogen hair density decreased by &#x02212;29% [<xref rid="B96-pharmaceuticals-18-00247" ref-type="bibr">96</xref>]. Similarly, in a randomized controlled placebo study, Loing et al. [<xref rid="B96-pharmaceuticals-18-00247" ref-type="bibr">96</xref>] analyzed the hair-growing activity of procyanidin oligomers in 43 subjects. The treated subjects showed a significantly improved hair density and number of total scalp hair.</p><p>Moreover, Seok et al. [<xref rid="B108-pharmaceuticals-18-00247" ref-type="bibr">108</xref>], in a double-masked, controlled, placebo clinical trial, studied the efficacy of <italic toggle="yes">Cistanche tubulosa</italic> and <italic toggle="yes">Laminaria japonica</italic> to promote hair growth. A significant increase in density (test group: 23.29 n/cm<sup>2</sup> &#x000b1; 24.26, control: 10.35 n/cm<sup>2</sup> &#x000b1; 20.08, <italic toggle="yes">p</italic> &#x0003c; 0.05) and diameter (test group: 0.018 mm &#x000b1; 0.015, control: 0.003 mm &#x000b1; 0.013, <italic toggle="yes">p</italic> &#x0003c; 0.05) was found in the hair of the treated group. Lastly, Kamimura et al. [<xref rid="B109-pharmaceuticals-18-00247" ref-type="bibr">109</xref>] in a double-blind clinical study reported the effects of procyanidin B-2 in 29 patients, showing a significant augment in the total number of hair (procyanidin B-2, 6.68 &#x000b1; 5.53 (mean &#x000b1; ED)/0.25 cm<sup>2</sup>; placebo, 0.08 &#x000b1; 4.56 (mean &#x000b1; ED)/0.25 cm<sup>2</sup>; <italic toggle="yes">p</italic> &#x0003c; 0.005) and terminal hair (procyanidin B-2, 1.99 &#x000b1; 2.58 (mean &#x000b1; ED)/0.25 cm<sup>2</sup>; placebo, &#x02212;0.82 &#x000b1; 3.40 (mean &#x000b1; ED)/0.25 cm<sup>2</sup>; <italic toggle="yes">p</italic> &#x0003c; 0.02).</p><p>Concerning skin fungal infections, despite a wide range of preclinical studies in the literature about polyphenol&#x02019;s antifungal activity [<xref rid="B41-pharmaceuticals-18-00247" ref-type="bibr">41</xref>,<xref rid="B43-pharmaceuticals-18-00247" ref-type="bibr">43</xref>,<xref rid="B110-pharmaceuticals-18-00247" ref-type="bibr">110</xref>], the clinical level of the data is very limited [<xref rid="B95-pharmaceuticals-18-00247" ref-type="bibr">95</xref>,<xref rid="B111-pharmaceuticals-18-00247" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceuticals-18-00247" ref-type="bibr">112</xref>]. In this sense, Ikeda et al. [<xref rid="B95-pharmaceuticals-18-00247" ref-type="bibr">95</xref>], in a double-masked, randomized, placebo-controlled trial, observed a significant improvement in tinea pedis. Similar results were reported in diabetic patients with onychomycosis [<xref rid="B113-pharmaceuticals-18-00247" ref-type="bibr">113</xref>]. <italic toggle="yes">Solanum chrysotrichu</italic> has proven to be another useful phyto drug [<xref rid="B112-pharmaceuticals-18-00247" ref-type="bibr">112</xref>,<xref rid="B114-pharmaceuticals-18-00247" ref-type="bibr">114</xref>]. Herrera-Arellano et al. [<xref rid="B114-pharmaceuticals-18-00247" ref-type="bibr">114</xref>], in a controlled and randomized double-masked clinical trial, demonstrated a clinical efficacy of 92.16% in <italic toggle="yes">pityriasis capitis</italic> patients after the use of the extract. In addition, it has been reported that Brazilian green propolis causes a clinical improvement in tinea pedis interdigitalis, tinea corporis [<xref rid="B115-pharmaceuticals-18-00247" ref-type="bibr">115</xref>], tinea capitis, and tinea versicolor [<xref rid="B116-pharmaceuticals-18-00247" ref-type="bibr">116</xref>]. Finally, other polyphenols such as <italic toggle="yes">Ocimum gratissimum</italic> [<xref rid="B117-pharmaceuticals-18-00247" ref-type="bibr">117</xref>], <italic toggle="yes">Acalypha wilkesiana</italic> [<xref rid="B118-pharmaceuticals-18-00247" ref-type="bibr">118</xref>], <italic toggle="yes">Cymbopogon citratus</italic> [<xref rid="B119-pharmaceuticals-18-00247" ref-type="bibr">119</xref>], <italic toggle="yes">Cassia alata</italic> [<xref rid="B120-pharmaceuticals-18-00247" ref-type="bibr">120</xref>], and <italic toggle="yes">Melaleuca alternifolia</italic> [<xref rid="B121-pharmaceuticals-18-00247" ref-type="bibr">121</xref>] have demonstrated improvement in fungal infections.</p><p>On the other hand, various clinical studies assessed the efficacy of polyphenols in different types of dermatitis, obtaining mixed results. Two clinical trials related to atopic dermatitis (AD) were found: the first is a monocentric, randomized, controlled, double-blind study [<xref rid="B122-pharmaceuticals-18-00247" ref-type="bibr">122</xref>] that evaluated the efficacy and safety of a vitamin E, gallate, epigallocatechin, and grape seed procyanidin (MD2011001) topical cream in a sample of patients with mild-to-moderate AD for 28 days, in which a statistically significant difference was not observed when compared to placebo.</p><p>In a second randomized, double-masked, controlled, placebo trial performed by Mehrbani et al. [<xref rid="B98-pharmaceuticals-18-00247" ref-type="bibr">98</xref>], 52 adult subjects with mild-to-moderate AD were treated with lyophilized powdered milk serum rich in flavonoids, quercetin, kaempferol, and rutin or placebo [<xref rid="B98-pharmaceuticals-18-00247" ref-type="bibr">98</xref>]. The results were promising, with statistically significant improvement compared to placebo, regarding clinical manifestations such as elasticity, hydration, pruritus of affected skin, and diminished sleep disturbances; moreover, it was concluded that these improvements were prolonged 15 days after the treatment. Nevertheless, the data provided by these investigations do not allow us to individually assess the effect of polyphenols on AD [<xref rid="B123-pharmaceuticals-18-00247" ref-type="bibr">123</xref>].</p><p>Radiation dermatitis (RD) in oncologic patients has been a focus of polyphenol research. Several studies assessed topical epigallocatechin-3-gallate (EGCG), an active compound of green tea, to prevent and treat this affection. In the research carried out by Zhao et al. [<xref rid="B99-pharmaceuticals-18-00247" ref-type="bibr">99</xref>], the effect of EGCG in RD prevention was evaluated via a second phase, randomized, double-blind, controlled, placebo trial and performed in breast cancer patients treated with postoperative radiotherapy. Following EGCG treatment, the incidence, severity, and clinical manifestations showed a statistically significant decrease. Moreover, the same authors previously tested the tolerability of the therapy in a phase I clinical trial [<xref rid="B124-pharmaceuticals-18-00247" ref-type="bibr">124</xref>], where no significant increase in adverse effects was observed. In addition, a more recent phase I clinical trial by Xie et al. [<xref rid="B125-pharmaceuticals-18-00247" ref-type="bibr">125</xref>] evaluated the use of EGCG for RD in patients with thoracic cancer, observing improvement in sensibility, pruritus, redness, pain, burning, and traction sensations, with no adverse effects reported.</p><p>EGCG is not the only polyphenol studied for RD; silymarin, a flavonoid extracted from <italic toggle="yes">Silybum marianum</italic>, was assessed by Karbasforooshan et al. [<xref rid="B126-pharmaceuticals-18-00247" ref-type="bibr">126</xref>] in a randomized, double blind and controlled placebo clinical trial. In the study, 1% silymarin gel was applied to breast cancer patients for RD prevention. Even though all subjects developed RD by the end of the study, a delayed onset and decreased severity were observed in the silymarin group.</p><p>Furthermore, polyphenols are potential therapeutic agents for contact dermatitis (CD). Improvements in inflammation markers were observed, specifically lower levels of INF&#x003b3;, IL-4, IL-17, pentraxin 3, and NO and augmented levels of IL-10, in women with CD treated with 300 mg of polyphenols per day extracted from red grape seeds [<xref rid="B127-pharmaceuticals-18-00247" ref-type="bibr">127</xref>].</p><p>Lastly, regarding the use of polyphenols for treating and preventing skin cancer, even though a growing body of in vitro and in vivo experimental studies with promising results exist, currently, no clinical trials assessing the safety and efficacy of these compounds is available [<xref rid="B128-pharmaceuticals-18-00247" ref-type="bibr">128</xref>].</p></sec><sec id="sec4-pharmaceuticals-18-00247"><title>4. Bioavailability of Polyphenols and Routes of Administration</title><p>The bioavailability of polyphenols is a crucial issue in their therapeutic application. Despite their high bioactivity, the performance of polyphenols in vivo may be limited due to low water solubility, low lipophilicity, and inadequate molecular size; therefore, polyphenols suffer from structural instability in biological environments. All these characteristics lead to poor biodistribution, first-pass metabolism, poor penetration, and accumulation in the different organs [<xref rid="B129-pharmaceuticals-18-00247" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceuticals-18-00247" ref-type="bibr">130</xref>].</p><p>Nowadays, topical administration has become one of the most attractive routes for the pharmaceutical industry. This method of administration can overcome some of the drawbacks of oral administration, such as low bioavailability, while ensuring the continuous and stable release of the polyphenol at the site of action. However, normal skin possesses a formidable barrier to drug absorption, mainly due to its particular lipid composition and the stratum corneum tissue [<xref rid="B129-pharmaceuticals-18-00247" ref-type="bibr">129</xref>].</p><p>Nanomedicine represents a favorable tool to increase the bioavailability and activities of natural products [<xref rid="B131-pharmaceuticals-18-00247" ref-type="bibr">131</xref>]. Nanostructured delivery systems that allow for a more effective delivery of polyphenols to the skin are currently being developed [<xref rid="B130-pharmaceuticals-18-00247" ref-type="bibr">130</xref>]. Nanocarriers can improve the stability, bioavailability, and targeted delivery of active ingredients, allowing better penetration and efficacy in treating specific skin conditions [<xref rid="B132-pharmaceuticals-18-00247" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceuticals-18-00247" ref-type="bibr">133</xref>,<xref rid="B134-pharmaceuticals-18-00247" ref-type="bibr">134</xref>,<xref rid="B135-pharmaceuticals-18-00247" ref-type="bibr">135</xref>,<xref rid="B136-pharmaceuticals-18-00247" ref-type="bibr">136</xref>].</p></sec><sec id="sec5-pharmaceuticals-18-00247"><title>5. Natural Components Other than Polyphenols Being Used in Skin Conditions</title><p>While polyphenols represent a promising alternative in various dermatological therapies, other organic compounds, including terpenes and terpenoids, carotenoids, and benzoquinones, also exhibit beneficial properties for skin conditions [<xref rid="B137-pharmaceuticals-18-00247" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceuticals-18-00247" ref-type="bibr">138</xref>,<xref rid="B139-pharmaceuticals-18-00247" ref-type="bibr">139</xref>].</p><p>Terpenes and terpenoids are a broad class of organic compounds found in several plants, as well as in some insects and microorganisms. Due to their anti-inflammatory, anti-microbial, and anti-tumor effects, terpenoids have been studied for their possible effects on inflammatory skin conditions, <italic toggle="yes">Staphylococcus Aureus</italic> infections, impetigo, dermatomycosis, and in the prevention and treatment of skin cancer [<xref rid="B137-pharmaceuticals-18-00247" ref-type="bibr">137</xref>,<xref rid="B140-pharmaceuticals-18-00247" ref-type="bibr">140</xref>]. Fungal terpenes and terpenoids have demonstrated tyrosinase inhibition, suggesting their potential use in treating skin pigmentation disorders and melanogenesis-related cancers [<xref rid="B141-pharmaceuticals-18-00247" ref-type="bibr">141</xref>,<xref rid="B142-pharmaceuticals-18-00247" ref-type="bibr">142</xref>,<xref rid="B143-pharmaceuticals-18-00247" ref-type="bibr">143</xref>,<xref rid="B144-pharmaceuticals-18-00247" ref-type="bibr">144</xref>].</p><p>On the other hand, carotenoids constitute a specific type of terpenoid; within this classification, there are compounds such as lutein, canthaxanthin, &#x003b1;-carotene, &#x003b2;-carotene, and lycopene [<xref rid="B145-pharmaceuticals-18-00247" ref-type="bibr">145</xref>]. These molecules possess anti-inflammatory, anti-tumor, and antioxidant properties [<xref rid="B138-pharmaceuticals-18-00247" ref-type="bibr">138</xref>]. Recent interventional studies have proven the effects of lutein on UV light-induced carcinogenesis in animal models, as well as its beneficial effects on physiological skin parameters in humans, including antioxidant protection against UV light irradiation [<xref rid="B146-pharmaceuticals-18-00247" ref-type="bibr">146</xref>,<xref rid="B147-pharmaceuticals-18-00247" ref-type="bibr">147</xref>,<xref rid="B148-pharmaceuticals-18-00247" ref-type="bibr">148</xref>]. Similarly, clinical trials have confirmed the antioxidant activity of carotenoids and their capacity to improve erythematous affections. [<xref rid="B149-pharmaceuticals-18-00247" ref-type="bibr">149</xref>,<xref rid="B150-pharmaceuticals-18-00247" ref-type="bibr">150</xref>]. Moreover, canthaxanthin has demonstrated its utility in erythropoietic protoporphyria, a genetic disorder characterized by sun sensitivity [<xref rid="B151-pharmaceuticals-18-00247" ref-type="bibr">151</xref>].</p><p>Benzoquinones represent a different class of organic compounds, widely distributed in fungus, bacteria, arthropods, and plants. Embelin is a benzoquinone produced by the plant <italic toggle="yes">Embelia ribes</italic>, known by its pharmacological and therapeutic effects, including antioxidant, anti-inflammatory, and anti-tumor properties [<xref rid="B152-pharmaceuticals-18-00247" ref-type="bibr">152</xref>]. Numerous research studies have managed to show its capacity to inhibit leukocyte aggregation, suppressing TNF and IL-1, along with other inflammatory factors, and this ability might be useful in skin conditions such as psoriasis and dermatitis. Simultaneously, a variety of studies have pointed out the pro-apoptotic, anti-proliferative, anti-metastatic, anti-angiogenic, and anti-inflammatory qualities of the said compound, thus, representing a promising alternative for skin cancer treatment and prophylaxis [<xref rid="B152-pharmaceuticals-18-00247" ref-type="bibr">152</xref>,<xref rid="B153-pharmaceuticals-18-00247" ref-type="bibr">153</xref>,<xref rid="B154-pharmaceuticals-18-00247" ref-type="bibr">154</xref>].</p><p>Many natural sources with potential skin benefits remain underexplored. Future studies should prioritize the research of lesser-known plant extracts, marine compounds, and other natural resources to identify novel bioactive ingredients and their therapeutic role in skin disorders.</p></sec><sec sec-type="conclusions" id="sec6-pharmaceuticals-18-00247"><title>6. Conclusions</title><p>Dermatologic disorders continue to be among the most frequently encountered and challenging medical conditions in contemporary medicine. Due to their intricate and multifaceted pathophysiological mechanisms, researchers have been actively pursuing and evaluating novel therapeutic alternatives for their management over the past several decades. Within this evolving therapeutic landscape, polyphenols have emerged as a particularly promising group of metabolites, distinguished by their remarkable ability to produce a diverse array of beneficial effects&#x02014;including potent antioxidant, anti-inflammatory, antimicrobial, antitumoral, and DNA-repairing properties&#x02014;through multiple cellular and molecular mechanisms in various dermatological conditions.</p><p>In this dynamic context, the extensive body of preclinical evidence supports and validates the potential therapeutic applications of polyphenols in addressing the underlying pathogenic processes of numerous dermatological conditions, including but not limited to acne vulgaris, various forms of dermatitis, cutaneous fungal infections, different patterns of alopecia, and several types of skin cancer. Despite these positive preclinical findings, the current landscape of clinical trial evidence remains notably limited in scope and depth. Therefore, there exists a pressing need for additional high-quality clinical research studies characterized by larger patient populations, extended follow-up observation periods, and more rigorous methodological frameworks to comprehensively evaluate and definitively establish the clinical efficacy and practical applications of polyphenol-based interventions in the treatment of dermatological disorders. Furthermore, the development of novel approaches dedicated to boost the natural properties of these molecules by enhancing characteristics such as absorption, solubility, and bioavailability, among others, represents a promising field of research in modern phytotherapy.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: &#x000c1;.O., J.S., J.L.P., R.S., B.G. and M.P.D.; methodology J.S., &#x000c1;.O., J.L.P. and M.C.; investigation &#x000c1;.O., J.L.P., R.S., N.G., B.G. and M.P.D.; writing&#x02014;review and editing &#x000c1;.O., J.L.P., M.P.D., R.S., N.G., B.G., J.C.C.-V., R.C., G.C. and M.C.; supervision M.C., J.C.C.-V., R.C. and G.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">GBD</td><td align="left" valign="middle" rowspan="1" colspan="1">Global Burden Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SD</td><td align="left" valign="middle" rowspan="1" colspan="1">Skin disorders</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AV</td><td align="left" valign="middle" rowspan="1" colspan="1">Acne vulgaris</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TPCLE</td><td align="left" valign="middle" rowspan="1" colspan="1">Total phenolic content leaf extract </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-8</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-1&#x003b2;</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-1&#x003b2;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor Necrosis Factor Alpha </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPK</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-Activated Protein Kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF-kB</td><td align="left" valign="middle" rowspan="1" colspan="1">Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MPP-9</td><td align="left" valign="middle" rowspan="1" colspan="1">Matrix Metalloproteinase 9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLR2</td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-like receptor 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Messenger RNA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Nitrous Oxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Intercellular Adhesion Molecule-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COX-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclooxygenase-2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COX-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclooxygenase-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JNK</td><td align="left" valign="middle" rowspan="1" colspan="1">c-Jun N-terminal kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KAS-III</td><td align="left" valign="middle" rowspan="1" colspan="1">3-Ketoacyl ACP synthase </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QML</td><td align="left" valign="middle" rowspan="1" colspan="1">Quercus mongolica leaf extract</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD</td><td align="left" valign="middle" rowspan="1" colspan="1">Pedunculagin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-6</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PP</td><td align="left" valign="middle" rowspan="1" colspan="1">Pomegranate peels</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5&#x003b1;AR-1</td><td align="left" valign="middle" rowspan="1" colspan="1">5&#x003b1; reductase type 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BK</td><td align="left" valign="middle" rowspan="1" colspan="1">Bokusoku </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AD</td><td align="left" valign="middle" rowspan="1" colspan="1">Atopic dermatitis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCS</td><td align="left" valign="middle" rowspan="1" colspan="1">Topical corticosteroids </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CI</td><td align="left" valign="middle" rowspan="1" colspan="1">Calcineurin inhibitors </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-4</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERK</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular Signal-Regulated Kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IgE</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunoglobulin E</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TSLP</td><td align="left" valign="middle" rowspan="1" colspan="1">Thymic Stromal Lymphopoietin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TTLE</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Tambourissa trichophylla</italic> leaf extract</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AP</td><td align="left" valign="middle" rowspan="1" colspan="1">Acacia polyphenol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">STB</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Schizonepeta tenuifolia</italic> Briquet </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AOM</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Alpinia oxyphylla</italic> Miquel </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CD</td><td align="left" valign="middle" rowspan="1" colspan="1">Contact dermatitis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mTOR</td><td align="left" valign="middle" rowspan="1" colspan="1">Mammalian Target of Rapamycin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLR4</td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-like receptor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SIRT1</td><td align="left" valign="middle" rowspan="1" colspan="1">Sirtuin 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IGF-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Insulin-like Growth Factor 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Keratinocyte growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TERT</td><td align="left" valign="middle" rowspan="1" colspan="1">Telomerase reverse transcriptase </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular Endothelial Growth Factor </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DPC</td><td align="left" valign="middle" rowspan="1" colspan="1">Dermal papilla cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Platelet-derived Growth Factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Epidermal Growth Factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DHT</td><td align="left" valign="middle" rowspan="1" colspan="1">Dihydrotestosterone</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GA</td><td align="left" valign="middle" rowspan="1" colspan="1">Gallic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ellagic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CYP51</td><td align="left" valign="middle" rowspan="1" colspan="1">Sterol 14&#x003b1;-demethylase P450</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SE</td><td align="left" valign="middle" rowspan="1" colspan="1">Squalane Epoxidase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CA</td><td align="left" valign="middle" rowspan="1" colspan="1">Caffeic Acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LicoA</td><td align="left" valign="middle" rowspan="1" colspan="1">Licochalcone A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Fatty acid synthase </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDK</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclin-Dependent Kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATP</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine triphosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMP</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitochondrial membrane potential </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ISO</td><td align="left" valign="middle" rowspan="1" colspan="1">Isoquercitrin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SOD</td><td align="left" valign="middle" rowspan="1" colspan="1">Superoxide Dismutase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5-LOX</td><td align="left" valign="middle" rowspan="1" colspan="1">5-Lipooxygenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HL</td><td align="left" valign="middle" rowspan="1" colspan="1">Hair loss</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AGA</td><td align="left" valign="middle" rowspan="1" colspan="1">Androgenic alopecia </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HF</td><td align="left" valign="middle" rowspan="1" colspan="1">Hair follicle</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TE</td><td align="left" valign="middle" rowspan="1" colspan="1">Telogen effluvium </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">Hydrogen peroxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALP</td><td align="left" valign="middle" rowspan="1" colspan="1">Alkaline phosphatase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ORSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Outer root sheath cells </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PM</td><td align="left" valign="middle" rowspan="1" colspan="1">Polygonum multiflorum</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TSG</td><td align="left" valign="middle" rowspan="1" colspan="1">2,3,5,4-Tetrahydroxystilbene-2-<italic toggle="yes">O</italic>-&#x003b2;-<sc>d</sc>-glucoside</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AR</td><td align="left" valign="middle" rowspan="1" colspan="1">Androgenic receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UV</td><td align="left" valign="middle" rowspan="1" colspan="1">Ultraviolet</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NMSC </td><td align="left" valign="middle" rowspan="1" colspan="1">Non-Melanoma Skin Cancer </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Basal Cell Carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Squamous cell carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma Skin Cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CPD</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclobutane pyrimidine dimer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NER</td><td align="left" valign="middle" rowspan="1" colspan="1">Nucleotide Excision Repair</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PI3K</td><td align="left" valign="middle" rowspan="1" colspan="1">Phosphatidylinositol 3 Kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AKT</td><td align="left" valign="middle" rowspan="1" colspan="1">Kinase protein B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TP</td><td align="left" valign="middle" rowspan="1" colspan="1">Tea polyphenol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ETR</td><td align="left" valign="middle" rowspan="1" colspan="1">Erythematotelangiectatic Rosacea</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PPR</td><td align="left" valign="middle" rowspan="1" colspan="1">Papulopustular Rosacea</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGCG</td><td align="left" valign="middle" rowspan="1" colspan="1">Epigallocatechin gallate </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RD</td><td align="left" valign="middle" rowspan="1" colspan="1">Radiation dermatitis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">INF&#x003b3;</td><td align="left" valign="middle" rowspan="1" colspan="1">Interferon-Gamma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-17</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-17</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-10</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin-10</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00247"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortiz</surname><given-names>A.</given-names></name>
<name><surname>Herrera</surname><given-names>T.</given-names></name>
<name><surname>del Molino</surname><given-names>C.P.</given-names></name>
<name><surname>Pi&#x000f1;eiro</surname><given-names>F.</given-names></name>
<name><surname>Perales</surname><given-names>M.L.</given-names></name>
<name><surname>Mu&#x000f1;oz</surname><given-names>P.</given-names></name>
</person-group><article-title>Epidemiolog&#x000ed;a de las enfermedades dermatologicas en atencion primaria</article-title><source>Rev. Espa&#x000f1;ola Salud P&#x000fa;blica</source><year>1992</year><volume>66</volume><fpage>71</fpage><lpage>82</lpage></element-citation></ref><ref id="B2-pharmaceuticals-18-00247"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hay</surname><given-names>R.J.</given-names></name>
<name><surname>Johns</surname><given-names>N.E.</given-names></name>
<name><surname>Williams</surname><given-names>H.C.</given-names></name>
<name><surname>Bolliger</surname><given-names>I.</given-names></name>
<name><surname>Dellavalle</surname><given-names>R.P.</given-names></name>
<name><surname>Margolis</surname><given-names>D.J.</given-names></name>
<name><surname>Marks</surname><given-names>R.</given-names></name>
<name><surname>Naldi</surname><given-names>L.</given-names></name>
<name><surname>Weinstock</surname><given-names>M.A.</given-names></name>
<name><surname>Wulf</surname><given-names>S.K.</given-names></name>
<etal/>
</person-group><article-title>The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions</article-title><source>J. Investig. Dermatol.</source><year>2014</year><volume>134</volume><fpage>1527</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.446</pub-id><pub-id pub-id-type="pmid">24166134</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00247"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>S.</given-names></name>
<name><surname>Mehrmal</surname><given-names>S.</given-names></name>
<name><surname>Uppal</surname><given-names>P.</given-names></name>
<name><surname>Giesey</surname><given-names>R.L.</given-names></name>
<name><surname>Delost</surname><given-names>M.E.</given-names></name>
<name><surname>Delost</surname><given-names>G.R.</given-names></name>
</person-group><article-title>Burden of skin disease and associated socioeconomic status in Europe: An ecologic study from the Global Burden of Disease Study 2017</article-title><source>JAAD Int.</source><year>2020</year><volume>1</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.jdin.2020.07.001</pub-id><pub-id pub-id-type="pmid">34409328</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00247"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salazar</surname><given-names>J.</given-names></name>
<name><surname>Cano</surname><given-names>C.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>J.L.</given-names></name>
<name><surname>Castro</surname><given-names>A.</given-names></name>
<name><surname>D&#x000ed;az</surname><given-names>M.P.</given-names></name>
<name><surname>Garrido</surname><given-names>B.</given-names></name>
<name><surname>Carrasquero</surname><given-names>R.</given-names></name>
<name><surname>Chac&#x000ed;n</surname><given-names>M.</given-names></name>
<name><surname>Velasco</surname><given-names>M.</given-names></name>
<name><surname>D&#x02019;marco</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Role of Dietary Polyphenols in Adipose Tissue Browning: A Narrative Review</article-title><source>Curr. Pharm. Des.</source><year>2020</year><volume>26</volume><fpage>4444</fpage><lpage>4460</lpage><pub-id pub-id-type="doi">10.2174/1381612826666200701211422</pub-id><pub-id pub-id-type="pmid">32611294</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00247"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dzia&#x00142;o</surname><given-names>M.</given-names></name>
<name><surname>Mierziak</surname><given-names>J.</given-names></name>
<name><surname>Korzun</surname><given-names>U.</given-names></name>
<name><surname>Preisner</surname><given-names>M.</given-names></name>
<name><surname>Szopa</surname><given-names>J.</given-names></name>
<name><surname>Kulma</surname><given-names>A.</given-names></name>
</person-group><article-title>The Potential of Plant Phenolics in Prevention and Therapy of Skin Disorders</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>160</elocation-id><!--<pub-id pub-id-type="pmcid">PMC4783894</pub-id>--><pub-id pub-id-type="doi">10.3390/ijms17020160</pub-id><pub-id pub-id-type="pmid">26901191</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00247"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Lima Cherubim</surname><given-names>D.J.</given-names></name>
<name><surname>Buzanello Martins</surname><given-names>C.V.</given-names></name>
<name><surname>Oliveira Fari&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>da Silva de Lucca</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Polyphenols as natural antioxidants in cosmetics applications</article-title><source>J. Cosmet. Dermatol.</source><year>2020</year><volume>19</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1111/jocd.13093</pub-id><pub-id pub-id-type="pmid">31389656</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00247"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosina</surname><given-names>P.</given-names></name>
<name><surname>Palonc&#x000fd;ov&#x000e1;</surname><given-names>M.</given-names></name>
<name><surname>Rajnochov&#x000e1; Svobodov&#x000e1;</surname><given-names>A.</given-names></name>
<name><surname>Z&#x000e1;le&#x00161;&#x000e1;k</surname><given-names>B.</given-names></name>
<name><surname>Biedermann</surname><given-names>D.</given-names></name>
<name><surname>Ulrichov&#x000e1;</surname><given-names>J.</given-names></name>
<name><surname>Vost&#x000e1;lov&#x000e1;</surname><given-names>J.</given-names></name>
</person-group><article-title>Dermal Delivery of Selected Polyphenols from <italic toggle="yes">Silybum marianum</italic>. Theoretical and Experimental Study</article-title><source>Molecules</source><year>2018</year><volume>24</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24010061</pub-id><pub-id pub-id-type="pmid">30586949</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00247"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chilicka</surname><given-names>K.</given-names></name>
<name><surname>Gold</surname><given-names>M.H.</given-names></name>
<name><surname>Nowicka</surname><given-names>D.</given-names></name>
</person-group><article-title>Acne vulgaris and the most popular and new cosmetological treatments</article-title><source>J. Cosmet. Dermatol.</source><year>2023</year><volume>22</volume><fpage>1946</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1111/jocd.15757</pub-id><pub-id pub-id-type="pmid">37062752</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00247"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vasam</surname><given-names>M.</given-names></name>
<name><surname>Korutla</surname><given-names>S.</given-names></name>
<name><surname>Bohara</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances</article-title><source>Biochem. Biophys. Rep.</source><year>2023</year><volume>36</volume><elocation-id>101578</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbrep.2023.101578</pub-id><pub-id pub-id-type="pmid">38076662</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00247"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheon</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Jeon</surname><given-names>D.</given-names></name>
<name><surname>Shin</surname><given-names>H.-C.</given-names></name>
<name><surname>Kim</surname><given-names>Y.</given-names></name>
</person-group><article-title>Target Proteins of Phloretin for Its Anti-Inflammatory and Antibacterial Activities Against Propionibacterium acnes-Induced Skin Infection</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>1319</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24071319</pub-id><pub-id pub-id-type="pmid">30987239</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00247"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.-C.</given-names></name>
<name><surname>Tsai</surname><given-names>T.-H.</given-names></name>
<name><surname>Huang</surname><given-names>C.-J.</given-names></name>
<name><surname>Li</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Chyuan</surname><given-names>J.-H.</given-names></name>
<name><surname>Chuang</surname><given-names>L.-T.</given-names></name>
<name><surname>Tsai</surname><given-names>P.-J.</given-names></name>
</person-group><article-title>Inhibitory Effects of Wild Bitter Melon Leaf Extract on <italic toggle="yes">Propionibacterium acnes</italic>-Induced Skin Inflammation in Mice and Cytokine Production In Vitro</article-title><source>Food Funct.</source><year>2015</year><volume>6</volume><fpage>2550</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1039/C5FO00550G</pub-id><pub-id pub-id-type="pmid">26098998</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00247"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>L.-T.</given-names></name>
<name><surname>Tsai</surname><given-names>T.-H.</given-names></name>
<name><surname>Lien</surname><given-names>T.-J.</given-names></name>
<name><surname>Huang</surname><given-names>W.-C.</given-names></name>
<name><surname>Liu</surname><given-names>J.-J.</given-names></name>
<name><surname>Chang</surname><given-names>H.</given-names></name>
<name><surname>Chang</surname><given-names>M.-L.</given-names></name>
<name><surname>Tsai</surname><given-names>P.-J.</given-names></name>
</person-group><article-title>Ethanolic Extract of <italic toggle="yes">Origanum vulgare</italic> Suppresses <italic toggle="yes">Propionibacterium acnes</italic>-Induced Inflammatory Responses in Human Monocyte and Mouse Ear Edema Models</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>1987</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23081987</pub-id><pub-id pub-id-type="pmid">30096960</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00247"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chrz&#x00105;szcz</surname><given-names>M.</given-names></name>
<name><surname>Miazga-Karska</surname><given-names>M.</given-names></name>
<name><surname>Klimek</surname><given-names>K.</given-names></name>
<name><surname>Granica</surname><given-names>S.</given-names></name>
<name><surname>Tch&#x000f3;rzewska</surname><given-names>D.</given-names></name>
<name><surname>Ginalska</surname><given-names>G.</given-names></name>
<name><surname>Szewczyk</surname><given-names>K.</given-names></name>
</person-group><article-title>Extracts from <italic toggle="yes">Cephalaria Uralensis</italic> (Murray) Roem. &#x00026; Schult. and <italic toggle="yes">Cephalaria Gigantea</italic> (Ledeb.) Bobrov as Potential Agents for Treatment of Acne Vulgaris: Chemical Characterization and In Vitro Biological Evaluation</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><elocation-id>796</elocation-id><pub-id pub-id-type="doi">10.3390/antiox9090796</pub-id><pub-id pub-id-type="pmid">32859126</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00247"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albouchi</surname><given-names>F.</given-names></name>
<name><surname>Avola</surname><given-names>R.</given-names></name>
<name><surname>Dico</surname><given-names>G.M.L.</given-names></name>
<name><surname>Calabrese</surname><given-names>V.</given-names></name>
<name><surname>Graziano</surname><given-names>A.C.E.</given-names></name>
<name><surname>Abderrabba</surname><given-names>M.</given-names></name>
<name><surname>Cardile</surname><given-names>V.</given-names></name>
</person-group><article-title><italic toggle="yes">Melaleuca styphelioides</italic> Sm. Polyphenols Modulate Interferon Gamma/Histamine-Induced Inflammation in Human NCTC 2544 Keratinocytes</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2526</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23102526</pub-id><pub-id pub-id-type="pmid">30279388</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00247"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Hwang</surname><given-names>I.H.</given-names></name>
<name><surname>Park</surname><given-names>D.H.</given-names></name>
<name><surname>Lee</surname><given-names>E.K.</given-names></name>
<name><surname>Kim</surname><given-names>M.J.</given-names></name>
<name><surname>Lee</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Anti-Acne Vulgaris Effects of Pedunculagin from the Leaves of <italic toggle="yes">Quercus mongolica</italic> by Anti-Inflammatory Activity and 5&#x003b1;-Reductase Inhibition</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>2154</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25092154</pub-id><pub-id pub-id-type="pmid">32380665</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00247"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Hou</surname><given-names>C.</given-names></name>
</person-group><article-title>Pomegranate peel polyphenols inhibits inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4/NF-&#x003ba;B pathway activation</article-title><source>Food Nutr. Res.</source><year>2019</year><volume>63</volume><fpage>3392</fpage><pub-id pub-id-type="doi">10.29219/fnr.v63.3392</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-18-00247"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koseki</surname><given-names>J.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Matsubara</surname><given-names>Y.</given-names></name>
<name><surname>Tsuchiya</surname><given-names>K.</given-names></name>
<name><surname>Mizuhara</surname><given-names>Y.</given-names></name>
<name><surname>Sekiguchi</surname><given-names>K.</given-names></name>
<name><surname>Nishimura</surname><given-names>H.</given-names></name>
<name><surname>Watanabe</surname><given-names>J.</given-names></name>
<name><surname>Kaneko</surname><given-names>A.</given-names></name>
<name><surname>Hattori</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Inhibition of Rat 5&#x003b1;-Reductase Activity and Testosterone-Induced Sebum Synthesis in Hamster Sebocytes by an Extract of Quercus acutissima Cortex</article-title><source>Evid.-Based Complement. Alternat. Med.</source><year>2015</year><volume>2015</volume><fpage>853846</fpage><pub-id pub-id-type="doi">10.1155/2015/853846</pub-id><pub-id pub-id-type="pmid">25709710</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00247"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>D.Y.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Ryu</surname><given-names>J.-H.</given-names></name>
</person-group><article-title>Prenylated Polyphenols from <italic toggle="yes">Broussonetia kazinoki</italic> as Inhibitors of Nitric Oxide Production</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>639</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23030639</pub-id><pub-id pub-id-type="pmid">29534539</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00247"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanei</surname><given-names>R.</given-names></name>
</person-group><article-title>Atopic Dermatitis in Older Adults: A Review of Treatment Options</article-title><source>Drugs Aging</source><year>2020</year><volume>37</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s40266-020-00750-5</pub-id><pub-id pub-id-type="pmid">32086792</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00247"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bridgman</surname><given-names>A.C.</given-names></name>
<name><surname>Qureshi</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Tabung</surname><given-names>F.K.</given-names></name>
<name><surname>Cho</surname><given-names>E.</given-names></name>
<name><surname>Drucker</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Inflammatory dietary pattern and incident psoriasis, psoriatic arthritis, and atopic dermatitis in women: A cohort study</article-title><source>J. Am. Acad. Dermatol.</source><year>2019</year><volume>80</volume><fpage>1682</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2019.02.038</pub-id><pub-id pub-id-type="pmid">30797850</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00247"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>X.-K.</given-names></name>
</person-group><article-title>Oxidative Stress in Atopic Dermatitis</article-title><source>Oxid. Med. Cell. Longev.</source><year>2016</year><volume>2016</volume><fpage>2721469</fpage><pub-id pub-id-type="doi">10.1155/2016/2721469</pub-id><pub-id pub-id-type="pmid">27006746</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00247"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kingkaw</surname><given-names>A.</given-names></name>
<name><surname>Nakphaichit</surname><given-names>M.</given-names></name>
<name><surname>Suratannon</surname><given-names>N.</given-names></name>
<name><surname>Nitisinprasert</surname><given-names>S.</given-names></name>
<name><surname>Wongoutong</surname><given-names>C.</given-names></name>
<name><surname>Chatchatee</surname><given-names>P.</given-names></name>
<name><surname>Krobthong</surname><given-names>S.</given-names></name>
<name><surname>Charoenlappanit</surname><given-names>S.</given-names></name>
<name><surname>Roytrakul</surname><given-names>S.</given-names></name>
<name><surname>Vongsangnak</surname><given-names>W.</given-names></name>
</person-group><article-title>Analysis of the infant gut microbiome reveals metabolic functional roles associated with healthy infants and infants with atopic dermatitis using metaproteomics</article-title><source>PeerJ</source><year>2020</year><volume>8</volume><fpage>e9988</fpage><pub-id pub-id-type="doi">10.7717/peerj.9988</pub-id><pub-id pub-id-type="pmid">33033661</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00247"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gil</surname><given-names>T.-Y.</given-names></name>
<name><surname>Kang</surname><given-names>Y.-M.</given-names></name>
<name><surname>Eom</surname><given-names>Y.-J.</given-names></name>
<name><surname>Hong</surname><given-names>C.-H.</given-names></name>
<name><surname>An</surname><given-names>H.-J.</given-names></name>
</person-group><article-title>Anti-Atopic Dermatitis Effect of <italic toggle="yes">Seaweed Fulvescens</italic> Extract via Inhibiting the STAT1 Pathway</article-title><source>Mediat. Inflamm.</source><year>2019</year><volume>2019</volume><fpage>3760934</fpage><pub-id pub-id-type="doi">10.1155/2019/3760934</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-18-00247"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>D.H.</given-names></name>
<name><surname>Park</surname><given-names>J.K.</given-names></name>
<name><surname>Choi</surname><given-names>J.</given-names></name>
<name><surname>Jang</surname><given-names>H.</given-names></name>
<name><surname>Seol</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Anti-inflammatory effects of natural flavonoid diosmetin in IL-4 and LPS-induced macrophage activation and atopic dermatitis model</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>89</volume><fpage>107046</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.107046</pub-id><pub-id pub-id-type="pmid">33045572</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00247"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.N.</given-names></name>
<name><surname>Shin</surname><given-names>S.A.</given-names></name>
<name><surname>Choo</surname><given-names>G.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Park</surname><given-names>Y.S.</given-names></name>
<name><surname>Kim</surname><given-names>B.S.</given-names></name>
<name><surname>Kim</surname><given-names>S.K.</given-names></name>
<name><surname>Cho</surname><given-names>S.D.</given-names></name>
<name><surname>Nam</surname><given-names>J.S.</given-names></name>
<name><surname>Choi</surname><given-names>C.S.</given-names></name>
<etal/>
</person-group><article-title>Anti-inflammatory effect of quercetin and galangin in LPS-stimulated RAW264.7 macrophages and DNCB-induced atopic dermatitis animal models</article-title><source>Int. J. Mol. Med.</source><year>2018</year><volume>41</volume><fpage>888</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2017.3296</pub-id><pub-id pub-id-type="pmid">29207037</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00247"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jegal</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>N.-J.</given-names></name>
<name><surname>Kim</surname><given-names>T.-Y.</given-names></name>
<name><surname>Choi</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>S.W.</given-names></name>
<name><surname>Hang</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>S.-N.</given-names></name>
<name><surname>Yang</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Effect of Topically Applied <italic toggle="yes">Wikstroemia dolichantha</italic> Diels on the Development of Atopic Dermatitis-Like Skin Symptoms in Mice</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>914</elocation-id><pub-id pub-id-type="doi">10.3390/nu11040914</pub-id><pub-id pub-id-type="pmid">31018627</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00247"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sudarshan</surname><given-names>K.</given-names></name>
<name><surname>Yarlagadda</surname><given-names>S.</given-names></name>
<name><surname>Sengupta</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent Advances in the Synthesis of Diarylheptanoids</article-title><source>Chem. Asian J.</source><year>2024</year><volume>19</volume><fpage>e202400380</fpage><pub-id pub-id-type="doi">10.1002/asia.202400380</pub-id><pub-id pub-id-type="pmid">38744677</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00247"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fitoussi</surname><given-names>J.</given-names></name>
<name><surname>Virassamyna&#x000ef;k</surname><given-names>S.</given-names></name>
<name><surname>Callejon</surname><given-names>S.</given-names></name>
<name><surname>Weber</surname><given-names>S.</given-names></name>
<name><surname>Collet</surname><given-names>E.</given-names></name>
<name><surname>Scalia</surname><given-names>J.</given-names></name>
<name><surname>Chavagnac-Bonneville</surname><given-names>M.</given-names></name>
<name><surname>Trompezinski</surname><given-names>S.</given-names></name>
<name><surname>Sayag</surname><given-names>M.</given-names></name>
</person-group><article-title>Inhibition of thymic stromal lymphopoietin production to improve pruritus and quality of life in infants and children with atopic dermatitis</article-title><source>J. Cosmet. Dermatol.</source><year>2020</year><volume>19</volume><fpage>2061</fpage><lpage>2069</lpage><pub-id pub-id-type="doi">10.1111/jocd.13515</pub-id><pub-id pub-id-type="pmid">32583610</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00247"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sozmen</surname><given-names>S.C.</given-names></name>
<name><surname>Karaman</surname><given-names>M.</given-names></name>
<name><surname>Micili</surname><given-names>S.C.</given-names></name>
<name><surname>Isik</surname><given-names>S.</given-names></name>
<name><surname>Ayyildiz</surname><given-names>Z.A.</given-names></name>
<name><surname>Bagriyanik</surname><given-names>A.</given-names></name>
<name><surname>Uzuner</surname><given-names>N.</given-names></name>
<name><surname>Karaman</surname><given-names>O.</given-names></name>
</person-group><article-title>Resveratrol ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis-like lesions through effects on the epithelium</article-title><source>PeerJ</source><year>2016</year><volume>4</volume><fpage>e1889</fpage><pub-id pub-id-type="doi">10.7717/peerj.1889</pub-id><pub-id pub-id-type="pmid">27069818</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00247"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikarashi</surname><given-names>N.</given-names></name>
<name><surname>Fujitate</surname><given-names>N.</given-names></name>
<name><surname>Togashi</surname><given-names>T.</given-names></name>
<name><surname>Takayama</surname><given-names>N.</given-names></name>
<name><surname>Fukuda</surname><given-names>N.</given-names></name>
<name><surname>Kon</surname><given-names>R.</given-names></name>
<name><surname>Sakai</surname><given-names>H.</given-names></name>
<name><surname>Kamei</surname><given-names>J.</given-names></name>
<name><surname>Sugiyama</surname><given-names>K.</given-names></name>
</person-group><article-title>Acacia Polyphenol Ameliorates Atopic Dermatitis in Trimellitic Anhydride-Induced Model Mice via Changes in the Gut Microbiota</article-title><source>Foods</source><year>2020</year><volume>9</volume><elocation-id>773</elocation-id><pub-id pub-id-type="doi">10.3390/foods9060773</pub-id><pub-id pub-id-type="pmid">32545274</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00247"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Qiu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
</person-group><article-title><italic toggle="yes">Schizonepeta tenuifolia</italic> with <italic toggle="yes">Alpinia oxyphylla</italic> Alleviates Atopic Dermatitis and Improves the Gut Microbiome in Nc/Nga Mice</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>722</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12080722</pub-id><pub-id pub-id-type="pmid">32751987</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00247"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jegal</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>N.-J.</given-names></name>
<name><surname>Lee</surname><given-names>S.-Y.</given-names></name>
<name><surname>Jo</surname><given-names>B.-G.</given-names></name>
<name><surname>Bong</surname><given-names>S.-K.</given-names></name>
<name><surname>Kim</surname><given-names>S.-N.</given-names></name>
<name><surname>Yang</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Quercitrin, the Main Compound in <italic toggle="yes">Wikstroemia indica</italic>, Mitigates Skin Lesions in a Mouse Model of 2,4-Dinitrochlorobenzene-Induced Contact Hypersensitivity</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2020</year><volume>2020</volume><fpage>4307161</fpage><pub-id pub-id-type="doi">10.1155/2020/4307161</pub-id><pub-id pub-id-type="pmid">32695208</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00247"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.-H.</given-names></name>
<name><surname>Cho</surname><given-names>S.-H.</given-names></name>
<name><surname>Youn</surname><given-names>S.-K.</given-names></name>
<name><surname>Park</surname><given-names>J.-S.</given-names></name>
<name><surname>Choi</surname><given-names>J.T.</given-names></name>
<name><surname>Bak</surname><given-names>Y.-S.</given-names></name>
<name><surname>Yu</surname><given-names>Y.-B.</given-names></name>
<name><surname>Kim</surname><given-names>Y.K.</given-names></name>
</person-group><article-title>Epidemiological Characterization of Skin Fungal Infections Between the Years 2006 and 2010 in Korea</article-title><source>Osong Public Health Res. Perspect.</source><year>2015</year><volume>6</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.phrp.2015.10.012</pub-id><pub-id pub-id-type="pmid">26835243</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00247"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>T.C.</given-names></name>
<name><surname>Findley</surname><given-names>K.</given-names></name>
<name><surname>Dawson</surname><given-names>T.L.</given-names></name>
<name><surname>Scheynius</surname><given-names>A.</given-names></name>
<name><surname>Boekhout</surname><given-names>T.</given-names></name>
<name><surname>Cuomo</surname><given-names>C.A.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Saunders</surname><given-names>C.W.</given-names></name>
</person-group><article-title>Fungi on the Skin: Dermatophytes and Malassezia</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2014</year><volume>4</volume><fpage>a019802</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a019802</pub-id><pub-id pub-id-type="pmid">25085959</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00247"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hube</surname><given-names>B.</given-names></name>
<name><surname>Hay</surname><given-names>R.</given-names></name>
<name><surname>Brasch</surname><given-names>J.</given-names></name>
<name><surname>Veraldi</surname><given-names>S.</given-names></name>
<name><surname>Schaller</surname><given-names>M.</given-names></name>
</person-group><article-title>Dermatomycoses and inflammation: The adaptive balance between growth, damage, and survival</article-title><source>J. Mycol. Med.</source><year>2015</year><volume>25</volume><fpage>e44</fpage><lpage>e58</lpage><pub-id pub-id-type="doi">10.1016/j.mycmed.2014.11.002</pub-id><pub-id pub-id-type="pmid">25662199</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00247"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez-Rossi</surname><given-names>N.M.</given-names></name>
<name><surname>Peres</surname><given-names>N.T.A.</given-names></name>
<name><surname>Rossi</surname><given-names>A.</given-names></name>
</person-group><article-title>Pathogenesis of Dermatophytosis: Sensing the Host Tissue</article-title><source>Mycopathologia</source><year>2017</year><volume>182</volume><fpage>215</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1007/s11046-016-0057-9</pub-id><pub-id pub-id-type="pmid">27590362</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00247"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al Aboody</surname><given-names>M.S.</given-names></name>
<name><surname>Mickymaray</surname><given-names>S.</given-names></name>
</person-group><article-title>Anti-Fungal Efficacy and Mechanisms of Flavonoids</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9020045</pub-id><pub-id pub-id-type="pmid">31991883</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00247"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jord&#x000e1;</surname><given-names>T.</given-names></name>
<name><surname>Puig</surname><given-names>S.</given-names></name>
</person-group><article-title>Regulation of Ergosterol Biosynthesis in <italic toggle="yes">Saccharomyces cerevisiae</italic></article-title><source>Genes</source><year>2020</year><volume>11</volume><elocation-id>795</elocation-id><pub-id pub-id-type="doi">10.3390/genes11070795</pub-id><pub-id pub-id-type="pmid">32679672</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00247"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.-J.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Dawuti</surname><given-names>G.</given-names></name>
<name><surname>Dou</surname><given-names>Q.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>H.-G.</given-names></name>
<name><surname>Aibai</surname><given-names>S.</given-names></name>
</person-group><article-title>Antifungal Activity of Gallic Acid In Vitro and In Vivo</article-title><source>Phytother. Res.</source><year>2017</year><volume>31</volume><fpage>1039</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1002/ptr.5823</pub-id><pub-id pub-id-type="pmid">28524381</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00247"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.J.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Dawuti</surname><given-names>G.</given-names></name>
<name><surname>Aibai</surname><given-names>S.</given-names></name>
</person-group><article-title>Antifungal Activity of Ellagic Acid In Vitro and In Vivo</article-title><source>Phytother. Res.</source><year>2015</year><volume>29</volume><fpage>1019</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1002/ptr.5340</pub-id><pub-id pub-id-type="pmid">25919446</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00247"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cantelli</surname><given-names>B.A.M.</given-names></name>
<name><surname>Bitencourt</surname><given-names>T.A.</given-names></name>
<name><surname>Komoto</surname><given-names>T.T.</given-names></name>
<name><surname>Beleboni</surname><given-names>R.O.</given-names></name>
<name><surname>Marins</surname><given-names>M.</given-names></name>
<name><surname>Fachin</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Caffeic acid and licochalcone A interfere with the glyoxylate cycle of Trichophyton rubrum</article-title><source>Biomed. Pharmacother.</source><year>2017</year><volume>96</volume><fpage>1389</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.11.051</pub-id><pub-id pub-id-type="pmid">29174577</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00247"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maier</surname><given-names>T.</given-names></name>
<name><surname>Leibundgut</surname><given-names>M.</given-names></name>
<name><surname>Boehringer</surname><given-names>D.</given-names></name>
<name><surname>Ban</surname><given-names>N.</given-names></name>
</person-group><article-title>Structure and function of eukaryotic fatty acid synthases</article-title><source>Q. Rev. Biophys.</source><year>2010</year><volume>43</volume><fpage>373</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1017/S0033583510000156</pub-id><pub-id pub-id-type="pmid">20731893</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00247"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Da Silva</surname><given-names>C.R.</given-names></name>
<name><surname>De Andrade-Neto</surname><given-names>J.B.</given-names></name>
<name><surname>Campos</surname><given-names>R.D.S.</given-names></name>
<name><surname>Figueiredo</surname><given-names>N.S.</given-names></name>
<name><surname>Sampaio</surname><given-names>L.S.</given-names></name>
<name><surname>Magalh&#x000e3;es</surname><given-names>H.I.F.</given-names></name>
<name><surname>Cavalcanti</surname><given-names>B.C.</given-names></name>
<name><surname>Gaspar</surname><given-names>D.M.</given-names></name>
<name><surname>De Andrade</surname><given-names>G.M.</given-names></name>
<name><surname>Lima</surname><given-names>I.S.P.</given-names></name>
<etal/>
</person-group><article-title>Synergistic effect of the flavonoid catechin, quercetin, or epigallocatechin gallate with fluconazole induces apoptosis in Candida tropicalis resistant to fluconazole</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1468</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1128/AAC.00651-13</pub-id><pub-id pub-id-type="pmid">24366745</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00247"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bitencourt</surname><given-names>T.A.</given-names></name>
<name><surname>Komoto</surname><given-names>T.T.</given-names></name>
<name><surname>Massaroto</surname><given-names>B.G.</given-names></name>
<name><surname>Miranda</surname><given-names>C.E.S.</given-names></name>
<name><surname>Beleboni</surname><given-names>R.O.</given-names></name>
<name><surname>Marins</surname><given-names>M.</given-names></name>
<name><surname>Fachin</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum</article-title><source>BMC Complement. Altern. Med.</source><year>2013</year><volume>13</volume><elocation-id>229</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6882-13-229</pub-id><pub-id pub-id-type="pmid">24044691</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00247"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bitencourt</surname><given-names>T.A.</given-names></name>
<name><surname>TakahasiKomoto</surname><given-names>T.</given-names></name>
<name><surname>Marins</surname><given-names>M.</given-names></name>
<name><surname>Fachin</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Antifungal activity of flavonoids and modulation of expression of genes of fatty acid synthesis in the dermatophyte Trichophyton rubrum</article-title><source>BMC Proc.</source><year>2014</year><volume>8</volume><issue>(Suppl. S4)</issue><elocation-id>53</elocation-id><pub-id pub-id-type="doi">10.1186/1753-6561-8-S4-P53</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-18-00247"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bitencourt</surname><given-names>T.A.</given-names></name>
<name><surname>Macedo</surname><given-names>C.</given-names></name>
<name><surname>Franco</surname><given-names>M.E.</given-names></name>
<name><surname>Rocha</surname><given-names>M.C.</given-names></name>
<name><surname>Moreli</surname><given-names>I.S.</given-names></name>
<name><surname>Cantelli</surname><given-names>B.A.M.</given-names></name>
<name><surname>Sanches</surname><given-names>P.R.</given-names></name>
<name><surname>Beleboni</surname><given-names>R.O.</given-names></name>
<name><surname>Malavazi</surname><given-names>I.</given-names></name>
<name><surname>Passos</surname><given-names>G.A.</given-names></name>
<etal/>
</person-group><article-title>Trans-chalcone activity against Trichophyton rubrum relies on an interplay between signaling pathways related to cell wall integrity and fatty acid metabolism</article-title><source>BMC Genom.</source><year>2019</year><volume>20</volume><elocation-id>411</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-019-5792-0</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-18-00247"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaziano</surname><given-names>R.</given-names></name>
<name><surname>Campione</surname><given-names>E.</given-names></name>
<name><surname>Iacovelli</surname><given-names>F.</given-names></name>
<name><surname>Marino</surname><given-names>D.</given-names></name>
<name><surname>Pica</surname><given-names>F.</given-names></name>
<name><surname>Di Francesco</surname><given-names>P.</given-names></name>
<name><surname>Aquaro</surname><given-names>S.</given-names></name>
<name><surname>Menichini</surname><given-names>F.</given-names></name>
<name><surname>Falconi</surname><given-names>M.</given-names></name>
<name><surname>Bianchi</surname><given-names>L.</given-names></name>
</person-group><article-title>Antifungal activity of <italic toggle="yes">Cardiospermum halicacabum</italic> L. (Sapindaceae) against Trichophyton rubrum occurs through molecular interaction with fungal Hsp90</article-title><source>Drug Des. Dev. Ther.</source><year>2018</year><volume>12</volume><fpage>2185</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S155610</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-18-00247"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Da</surname><given-names>X.</given-names></name>
<name><surname>Nishiyama</surname><given-names>Y.</given-names></name>
<name><surname>Tie</surname><given-names>D.</given-names></name>
<name><surname>Hein</surname><given-names>K.Z.</given-names></name>
<name><surname>Yamamoto</surname><given-names>O.</given-names></name>
<name><surname>Morita</surname><given-names>E.</given-names></name>
</person-group><article-title>Antifungal Activity and Mechanism of Action of Ou-gon (<italic toggle="yes">Scutellaria</italic> Root Extract) Components Against Pathogenic Fungi</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>1683</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-38916-w</pub-id><pub-id pub-id-type="pmid">30737463</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00247"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Woo</surname><given-names>E.</given-names></name>
<name><surname>Lee</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Synergistic Antifungal Activity of Isoquercitrin: Apoptosis and Membrane Permeabilization Related to Reactive Oxygen Species in <italic toggle="yes">Candida albicans</italic></article-title><source>IUBMB Life</source><year>2019</year><volume>71</volume><fpage>283</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1002/iub.1973</pub-id><pub-id pub-id-type="pmid">30481395</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00247"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gomes</surname><given-names>N.G.M.</given-names></name>
<name><surname>Oliveira</surname><given-names>A.P.</given-names></name>
<name><surname>Cunha</surname><given-names>D.</given-names></name>
<name><surname>Pereira</surname><given-names>D.M.</given-names></name>
<name><surname>Valent&#x000e3;o</surname><given-names>P.</given-names></name>
<name><surname>Pinto</surname><given-names>E.</given-names></name>
<name><surname>Ara&#x000fa;jo</surname><given-names>L.</given-names></name>
<name><surname>Andrade</surname><given-names>P.B.</given-names></name>
</person-group><article-title>Flavonoid Composition of <italic toggle="yes">Salacia senegalensis</italic> (Lam.) DC. Leaves, Evaluation of Antidermatophytic Effects, and Potential Amelioration of the Associated Inflammatory Response</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>2530</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24142530</pub-id><pub-id pub-id-type="pmid">31295972</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00247"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tosti</surname><given-names>A.</given-names></name>
<name><surname>Gray</surname><given-names>J.</given-names></name>
</person-group><article-title>Assessment of Hair and Scalp Disorders</article-title><source>J. Investig. Dermatol. Symp. Proc.</source><year>2007</year><volume>12</volume><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/sj.jidsymp.5650051</pub-id><pub-id pub-id-type="pmid">18004293</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00247"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mysore</surname><given-names>V.</given-names></name>
<name><surname>Parthasaradhi</surname><given-names>A.</given-names></name>
<name><surname>Kharkar</surname><given-names>R.</given-names></name>
<name><surname>Ghoshal</surname><given-names>A.</given-names></name>
<name><surname>Ganjoo</surname><given-names>A.</given-names></name>
<name><surname>Ravichandran</surname><given-names>G.</given-names></name>
<name><surname>Saraswat</surname><given-names>A.</given-names></name>
<name><surname>Shah</surname><given-names>Y.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Remadevi</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Expert consensus on the management of androgenetic alopecia in India</article-title><source>Int. J. Trichology</source><year>2019</year><volume>11</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.4103/ijt.ijt_24_19</pub-id><pub-id pub-id-type="pmid">31360037</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00247"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simakou</surname><given-names>T.</given-names></name>
<name><surname>Butcher</surname><given-names>J.P.</given-names></name>
<name><surname>Reid</surname><given-names>S.</given-names></name>
<name><surname>Henriquez</surname><given-names>F.L.</given-names></name>
</person-group><article-title>Alopecia areata: A multifactorial autoimmune condition</article-title><source>J. Autoimmun.</source><year>2019</year><volume>98</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2018.12.001</pub-id><pub-id pub-id-type="pmid">30558963</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00247"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malkud</surname><given-names>S.</given-names></name>
</person-group><article-title>Telogen Effluvium: A Review</article-title><source>J. Clin. Diagn. Res.</source><year>2015</year><volume>9</volume><fpage>WE01</fpage><lpage>WE03</lpage><pub-id pub-id-type="doi">10.7860/JCDR/2015/15219.6492</pub-id><pub-id pub-id-type="pmid">26500992</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-18-00247"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>Z.</given-names></name>
<name><surname>Avci</surname><given-names>P.</given-names></name>
<name><surname>Hamblin</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Drug discovery for alopecia: Gone today, hair tomorrow</article-title><source>Expert Opin. Drug Discov.</source><year>2015</year><volume>10</volume><fpage>269</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1517/17460441.2015.1009892</pub-id><pub-id pub-id-type="pmid">25662177</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00247"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>O.S.</given-names></name>
<name><surname>Han</surname><given-names>J.H.</given-names></name>
<name><surname>Yoo</surname><given-names>H.G.</given-names></name>
<name><surname>Chung</surname><given-names>J.H.</given-names></name>
<name><surname>Cho</surname><given-names>K.H.</given-names></name>
<name><surname>Eun</surname><given-names>H.C.</given-names></name>
<name><surname>Kim</surname><given-names>K.H.</given-names></name>
</person-group><article-title>Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG)</article-title><source>Phytomedicine</source><year>2007</year><volume>14</volume><fpage>551</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2006.09.009</pub-id><pub-id pub-id-type="pmid">17092697</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00247"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wikramanayake</surname><given-names>T.C.</given-names></name>
<name><surname>Villasante</surname><given-names>A.C.</given-names></name>
<name><surname>Mauro</surname><given-names>L.M.</given-names></name>
<name><surname>Perez</surname><given-names>C.I.</given-names></name>
<name><surname>Schachner</surname><given-names>L.A.</given-names></name>
<name><surname>Jimenez</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Prevention and treatment of alopecia areata with quercetin in the C3H/HeJ mouse model</article-title><source>Cell. Stress. Chaperones</source><year>2012</year><volume>17</volume><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1007/s12192-011-0305-3</pub-id><pub-id pub-id-type="pmid">22042611</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00247"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Driskell</surname><given-names>R.R.</given-names></name>
<name><surname>Clavel</surname><given-names>C.</given-names></name>
<name><surname>Rendl</surname><given-names>M.</given-names></name>
<name><surname>Watt</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Hair follicle dermal papilla cells at a glance</article-title><source>J. Cell Sci.</source><year>2011</year><volume>124</volume><issue-part>Pt 8</issue-part><fpage>1179</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1242/jcs.082446</pub-id><pub-id pub-id-type="pmid">21444748</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00247"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madaan</surname><given-names>A.</given-names></name>
<name><surname>Joshi</surname><given-names>V.</given-names></name>
<name><surname>Kishore</surname><given-names>A.</given-names></name>
<name><surname>Verma</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Jaggi</surname><given-names>M.</given-names></name>
<name><surname>Sung</surname><given-names>Y.K.</given-names></name>
</person-group><article-title>In vitro Hair Growth Promoting Effects of Naringenin and Hesperetin on Human Dermal Papilla Cells and Keratinocytes</article-title><source>Am. J. Dermatol. Venereol.</source><year>2017</year><volume>6</volume><fpage>51</fpage><lpage>57</lpage></element-citation></ref><ref id="B60-pharmaceuticals-18-00247"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xing</surname><given-names>F.</given-names></name>
<name><surname>Yi</surname><given-names>W.J.</given-names></name>
<name><surname>Miao</surname><given-names>F.</given-names></name>
<name><surname>Su</surname><given-names>M.Y.</given-names></name>
<name><surname>Lei</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Baicalin increases hair follicle development by increasing canonical Wnt/&#x003b2;-catenin signaling and activating dermal papillar cells in mice</article-title><source>Int. J. Mol. Med.</source><year>2018</year><volume>41</volume><fpage>2079</fpage><lpage>2085</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3391</pub-id><pub-id pub-id-type="pmid">29336472</pub-id>
</element-citation></ref><ref id="B61-pharmaceuticals-18-00247"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Jing</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Morroniside regulates hair growth and cycle transition via activation of the Wnt/&#x003b2;-catenin signaling pathway</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>13785</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-32138-2</pub-id><pub-id pub-id-type="pmid">30213979</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-18-00247"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>J.H.</given-names></name>
<name><surname>Kwon</surname><given-names>O.S.</given-names></name>
<name><surname>Chung</surname><given-names>J.H.</given-names></name>
<name><surname>Cho</surname><given-names>K.H.</given-names></name>
<name><surname>Eun</surname><given-names>H.C.</given-names></name>
<name><surname>Kim</surname><given-names>K.H.</given-names></name>
</person-group><article-title>Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle</article-title><source>J. Dermatol. Sci.</source><year>2004</year><volume>34</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2004.01.002</pub-id><pub-id pub-id-type="pmid">15033191</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-18-00247"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>J.Y.</given-names></name>
<name><surname>Choi</surname><given-names>Y.-H.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Nam</surname><given-names>Y.J.</given-names></name>
<name><surname>Lee</surname><given-names>S.Y.</given-names></name>
<name><surname>Jeon</surname><given-names>J.H.</given-names></name>
<name><surname>Jin</surname><given-names>M.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
</person-group><article-title>Polygonum multiflorum extract support hair growth by elongating anagen phase and abrogating the effect of androgen in cultured human dermal papilla cells</article-title><source>BMC Complement. Med. Ther.</source><year>2020</year><volume>20</volume><elocation-id>144</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-020-02940-5</pub-id><pub-id pub-id-type="pmid">32398000</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-18-00247"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kubo</surname><given-names>C.</given-names></name>
<name><surname>Ogawa</surname><given-names>M.</given-names></name>
<name><surname>Uehara</surname><given-names>N.</given-names></name>
<name><surname>Katakura</surname><given-names>Y.</given-names></name>
</person-group><article-title>Fisetin Promotes Hair Growth by Augmenting TERT Expression</article-title><source>Front. Cell Dev. Biol.</source><year>2020</year><volume>8</volume><elocation-id>566617</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2020.566617</pub-id><pub-id pub-id-type="pmid">33178686</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-18-00247"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khazaei</surname><given-names>Z.</given-names></name>
<name><surname>Ghorat</surname><given-names>F.</given-names></name>
<name><surname>Jarrahi</surname><given-names>A.M.</given-names></name>
<name><surname>Adineh</surname><given-names>H.A.</given-names></name>
<name><surname>Sohrabivafa</surname><given-names>M.</given-names></name>
<name><surname>Goodarzi</surname><given-names>E.</given-names></name>
</person-group><article-title>Global incidence and mortality of skin cancer by histological subtype and its relationship with the human development index (HDI); an ecology study in 2018</article-title><source>World Cancer Res. J.</source><year>2019</year><volume>6</volume><fpage>e1265</fpage><pub-id pub-id-type="doi">10.32113/wcrj_20194_1265</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-18-00247"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fahradyan</surname><given-names>A.</given-names></name>
<name><surname>Howell</surname><given-names>A.C.</given-names></name>
<name><surname>Wolfswinkel</surname><given-names>E.M.</given-names></name>
<name><surname>Tsuha</surname><given-names>M.</given-names></name>
<name><surname>Sheth</surname><given-names>P.</given-names></name>
<name><surname>Wong</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Updates on the Management of Non-Melanoma Skin Cancer (NMSC)</article-title><source>Healthcare</source><year>2017</year><volume>5</volume><elocation-id>82</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare5040082</pub-id><pub-id pub-id-type="pmid">29104226</pub-id>
</element-citation></ref><ref id="B67-pharmaceuticals-18-00247"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohammadbeigi</surname><given-names>A.</given-names></name>
<name><surname>Khazaei</surname><given-names>S.</given-names></name>
<name><surname>Veisani</surname><given-names>Y.</given-names></name>
<name><surname>Delpisheh</surname><given-names>A.</given-names></name>
<name><surname>Jenabi</surname><given-names>E.</given-names></name>
</person-group><article-title>Global inequality in the incidence and mortality rate of melanoma skin cancer according to human development index: A country-level analysis</article-title><source>Egypt. J. Dermatol. Venerol.</source><year>2021</year><volume>41</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.4103/ejdv.ejdv_10_20</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-18-00247"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.T.</given-names></name>
<name><surname>Kempton</surname><given-names>S.J.</given-names></name>
<name><surname>Rao</surname><given-names>V.K.M.</given-names></name>
</person-group><article-title>The Economics of Skin Cancer: An Analysis of Medicare Payment Data</article-title><source>Plast. Reconstr. Surg. Glob. Open</source><year>2016</year><volume>4</volume><fpage>e868</fpage><pub-id pub-id-type="doi">10.1097/GOX.0000000000000826</pub-id><pub-id pub-id-type="pmid">27757333</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00247"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sajadimajd</surname><given-names>S.</given-names></name>
<name><surname>Bahramsoltani</surname><given-names>R.</given-names></name>
<name><surname>Iranpanah</surname><given-names>A.</given-names></name>
<name><surname>Patra</surname><given-names>J.K.</given-names></name>
<name><surname>Das</surname><given-names>G.</given-names></name>
<name><surname>Gouda</surname><given-names>S.</given-names></name>
<name><surname>Rahimi</surname><given-names>R.</given-names></name>
<name><surname>Rezaeiamiri</surname><given-names>E.</given-names></name>
<name><surname>Cao</surname><given-names>H.</given-names></name>
<name><surname>Giampieri</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Advances on Natural Polyphenols as Anticancer Agents for Skin Cancer</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>151</volume><fpage>104584</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104584</pub-id><pub-id pub-id-type="pmid">31809853</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-18-00247"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Chang</surname><given-names>L.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>W.</given-names></name>
<name><surname>Xia</surname><given-names>X.</given-names></name>
</person-group><article-title>Tea polyphenols inhibit the proliferation, migration, and invasion of melanoma cells through the down-regulation of TLR4</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2018</year><volume>32</volume><fpage>394632017739531</fpage><pub-id pub-id-type="doi">10.1177/0394632017739531</pub-id><pub-id pub-id-type="pmid">29359608</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-18-00247"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swalwell</surname><given-names>H.</given-names></name>
<name><surname>Latimer</surname><given-names>J.</given-names></name>
<name><surname>Haywood</surname><given-names>R.M.</given-names></name>
<name><surname>Birch-Machin</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Investigating the role of melanin in UVA/UVB- and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells</article-title><source>Free Radic. Biol. Med.</source><year>2012</year><volume>52</volume><fpage>626</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.11.019</pub-id><pub-id pub-id-type="pmid">22178978</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-18-00247"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikehata</surname><given-names>H.</given-names></name>
<name><surname>Mori</surname><given-names>T.</given-names></name>
<name><surname>Kamei</surname><given-names>Y.</given-names></name>
<name><surname>Douki</surname><given-names>T.</given-names></name>
<name><surname>Cadet</surname><given-names>J.</given-names></name>
<name><surname>Yamamoto</surname><given-names>M.</given-names></name>
</person-group><article-title>Wavelength- and Tissue-dependent Variations in the Mutagenicity of Cyclobutane Pyrimidine Dimers in Mouse Skin</article-title><source>Photochem. Photobiol.</source><year>2020</year><volume>96</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/php.13159</pub-id><pub-id pub-id-type="pmid">31461538</pub-id>
</element-citation></ref><ref id="B73-pharmaceuticals-18-00247"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chong</surname><given-names>Z.</given-names></name>
<name><surname>Matsuo</surname><given-names>H.</given-names></name>
<name><surname>Onoue</surname><given-names>S.</given-names></name>
<name><surname>Yamamoto</surname><given-names>H.</given-names></name>
<name><surname>Ito</surname><given-names>H.</given-names></name>
<name><surname>Katakura</surname><given-names>Y.</given-names></name>
</person-group><article-title>Identification of polyphenols that repair the ultraviolet-B-induced DNA damage via SIRT1-dependent XPC/XPA activation</article-title><source>J. Funct. Foods</source><year>2019</year><volume>54</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2019.01.017</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-18-00247"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xian</surname><given-names>D.</given-names></name>
<name><surname>Lai</surname><given-names>R.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Xiong</surname><given-names>X.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
</person-group><article-title>Emerging Perspective: Role of Increased ROS and Redox Imbalance in Skin Carcinogenesis</article-title><source>Oxid. Med. Cell. Longev.</source><year>2019</year><volume>2019</volume><fpage>8127362</fpage><pub-id pub-id-type="doi">10.1155/2019/8127362</pub-id><pub-id pub-id-type="pmid">31636809</pub-id>
</element-citation></ref><ref id="B75-pharmaceuticals-18-00247"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>Y.E.</given-names></name>
<name><surname>Bohl</surname><given-names>L.P.</given-names></name>
<name><surname>Braber</surname><given-names>N.L.V.</given-names></name>
<name><surname>Ballatore</surname><given-names>M.B.</given-names></name>
<name><surname>Escobar</surname><given-names>F.M.</given-names></name>
<name><surname>Bodoira</surname><given-names>R.</given-names></name>
<name><surname>Maestri</surname><given-names>D.M.</given-names></name>
<name><surname>Porporatto</surname><given-names>C.</given-names></name>
<name><surname>Cavaglieri</surname><given-names>L.R.</given-names></name>
<name><surname>Montenegro</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Polyphenols of peanut (<italic toggle="yes">Arachis hypogaea</italic> L.) skin as bioprotectors of normal cells. Studies of cytotoxicity, cytoprotection and interaction with ROS</article-title><source>J. Funct. Foods</source><year>2020</year><volume>67</volume><fpage>103862</fpage><pub-id pub-id-type="doi">10.1016/j.jff.2020.103862</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-18-00247"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eskandari</surname><given-names>M.</given-names></name>
<name><surname>Rembiesa</surname><given-names>J.</given-names></name>
<name><surname>Startait&#x00117;</surname><given-names>L.</given-names></name>
<name><surname>Holefors</surname><given-names>A.</given-names></name>
<name><surname>Valan&#x0010d;i&#x0016b;t&#x00117;</surname><given-names>A.</given-names></name>
<name><surname>Faridbod</surname><given-names>F.</given-names></name>
<name><surname>Ganjali</surname><given-names>M.R.</given-names></name>
<name><surname>Engblom</surname><given-names>J.</given-names></name>
<name><surname>Ruzgas</surname><given-names>T.</given-names></name>
</person-group><article-title>Polyphenol-hydrogen peroxide reactions in skin: In vitro model relevant to study ROS reactions at inflammation</article-title><source>Anal. Chim. Acta</source><year>2019</year><volume>1075</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2019.05.032</pub-id><pub-id pub-id-type="pmid">31196427</pub-id>
</element-citation></ref><ref id="B77-pharmaceuticals-18-00247"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ko</surname><given-names>J.-H.</given-names></name>
<name><surname>Sethi</surname><given-names>G.</given-names></name>
<name><surname>Um</surname><given-names>J.-Y.</given-names></name>
<name><surname>Shanmugam</surname><given-names>M.K.</given-names></name>
<name><surname>Arfuso</surname><given-names>F.</given-names></name>
<name><surname>Kumar</surname><given-names>A.P.</given-names></name>
<name><surname>Bishayee</surname><given-names>A.</given-names></name>
<name><surname>Ahn</surname><given-names>K.S.</given-names></name>
</person-group><article-title>The Role of Resveratrol in Cancer Therapy</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>2589</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18122589</pub-id><pub-id pub-id-type="pmid">29194365</pub-id>
</element-citation></ref><ref id="B78-pharmaceuticals-18-00247"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bridgeman</surname><given-names>B.B.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Ye</surname><given-names>B.</given-names></name>
<name><surname>Pelling</surname><given-names>J.C.</given-names></name>
<name><surname>Volpert</surname><given-names>O.V.</given-names></name>
<name><surname>Tong</surname><given-names>X.</given-names></name>
</person-group><article-title>Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention</article-title><source>Cell. Signal.</source><year>2016</year><volume>28</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2016.02.008</pub-id><pub-id pub-id-type="pmid">26876613</pub-id>
</element-citation></ref><ref id="B79-pharmaceuticals-18-00247"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arumugam</surname><given-names>G.</given-names></name>
<name><surname>Yadav</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Synergistic inhibitory actions of resveratrol, epigallocatechin-3-gallate, and diallyl trisulfide against skin cancer cell line A431 through mitochondrial caspase dependent pathway: A combinational drug approach</article-title><source>Med. Oncol.</source><year>2024</year><volume>41</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.1007/s12032-023-02292-3</pub-id><pub-id pub-id-type="pmid">38280077</pub-id>
</element-citation></ref><ref id="B80-pharmaceuticals-18-00247"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zujko-Kowalska</surname><given-names>K.</given-names></name>
<name><surname>Mas&#x00142;owska</surname><given-names>J.</given-names></name>
<name><surname>Kna&#x0015b;-Dawidziuk</surname><given-names>M.</given-names></name>
<name><surname>Hamulka</surname><given-names>J.</given-names></name>
<name><surname>Zujko</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Dietary Antioxidants May Support Cosmetic Treatment in Patients with Rosacea</article-title><source>Antioxidants</source><year>2024</year><volume>13</volume><elocation-id>381</elocation-id><pub-id pub-id-type="doi">10.3390/antiox13030381</pub-id><pub-id pub-id-type="pmid">38539914</pub-id>
</element-citation></ref><ref id="B81-pharmaceuticals-18-00247"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Searle</surname><given-names>T.</given-names></name>
<name><surname>Ali</surname><given-names>F.R.</given-names></name>
<name><surname>Carolides</surname><given-names>S.</given-names></name>
<name><surname>Al-Niaimi</surname><given-names>F.</given-names></name>
</person-group><article-title>Rosacea and Diet: What is New in 2021?</article-title><source>J. Clin. Aesthet. Dermatol.</source><year>2021</year><volume>14</volume><fpage>49</fpage><lpage>54</lpage></element-citation></ref><ref id="B82-pharmaceuticals-18-00247"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paiva-Santos</surname><given-names>A.C.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>T.</given-names></name>
<name><surname>Peixoto</surname><given-names>D.</given-names></name>
<name><surname>Pires</surname><given-names>P.C.</given-names></name>
<name><surname>Velsankar</surname><given-names>K.</given-names></name>
<name><surname>Jha</surname><given-names>N.K.</given-names></name>
<name><surname>Chavda</surname><given-names>V.P.</given-names></name>
<name><surname>Mohammad</surname><given-names>I.S.</given-names></name>
<name><surname>Cefali</surname><given-names>L.C.</given-names></name>
<name><surname>Mazzola</surname><given-names>P.G.</given-names></name>
<etal/>
</person-group><article-title>Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems</article-title><source>Mol. Pharm.</source><year>2023</year><volume>20</volume><fpage>3804</fpage><lpage>3828</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00324</pub-id><pub-id pub-id-type="pmid">37478169</pub-id>
</element-citation></ref><ref id="B83-pharmaceuticals-18-00247"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Tang</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>R.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
</person-group><article-title>Rosacea Treatment: Review and Update</article-title><source>Dermatol. Ther.</source><year>2021</year><volume>11</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s13555-020-00461-0</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-18-00247"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maden</surname><given-names>S.</given-names></name>
</person-group><article-title>Epidermal Skin Barrier and Skin Care in Rosacea: A Narrative Review</article-title><source>Dermis</source><year>2024</year><volume>4</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.35702/Derm.10015</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-18-00247"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dall&#x02019;Oglio</surname><given-names>F.</given-names></name>
<name><surname>Nasca</surname><given-names>M.R.</given-names></name>
<name><surname>Gerbino</surname><given-names>C.</given-names></name>
<name><surname>Micali</surname><given-names>G.</given-names></name>
</person-group><article-title>Advances in pharmacotherapy for rosacea: What is the current state of the art?</article-title><source>Expert Opin. Pharmacother.</source><year>2022</year><volume>23</volume><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1080/14656566.2022.2142907</pub-id><pub-id pub-id-type="pmid">36330970</pub-id>
</element-citation></ref><ref id="B86-pharmaceuticals-18-00247"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esp&#x000f3;sito</surname><given-names>A.C.C.</given-names></name>
<name><surname>Cassiano</surname><given-names>D.P.</given-names></name>
<name><surname>da Silva</surname><given-names>C.N.</given-names></name>
<name><surname>Lima</surname><given-names>P.B.</given-names></name>
<name><surname>Dias</surname><given-names>J.A.F.</given-names></name>
<name><surname>Hassun</surname><given-names>K.</given-names></name>
<name><surname>Bagatin</surname><given-names>E.</given-names></name>
<name><surname>Miot</surname><given-names>L.D.B.</given-names></name>
<name><surname>Miot</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Update on Melasma&#x02014;Part I: Pathogenesis</article-title><source>Dermatol. Ther.</source><year>2022</year><volume>12</volume><fpage>1967</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1007/s13555-022-00779-x</pub-id><pub-id pub-id-type="pmid">35904706</pub-id>
</element-citation></ref><ref id="B87-pharmaceuticals-18-00247"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Artzi</surname><given-names>O.</given-names></name>
<name><surname>Horovitz</surname><given-names>T.</given-names></name>
<name><surname>Bar-Ilan</surname><given-names>E.</given-names></name>
<name><surname>Shehadeh</surname><given-names>W.</given-names></name>
<name><surname>Koren</surname><given-names>A.</given-names></name>
<name><surname>Zusmanovitch</surname><given-names>L.</given-names></name>
<name><surname>Mehrabi</surname><given-names>J.N.</given-names></name>
<name><surname>Salameh</surname><given-names>F.</given-names></name>
<name><surname>Nelkenbaum</surname><given-names>G.I.</given-names></name>
<name><surname>Zur</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>The pathogenesis of melasma and implications for treatment</article-title><source>J. Cosmet. Dermatol.</source><year>2021</year><volume>20</volume><fpage>3432</fpage><lpage>3445</lpage><pub-id pub-id-type="doi">10.1111/jocd.14382</pub-id><pub-id pub-id-type="pmid">34411403</pub-id>
</element-citation></ref><ref id="B88-pharmaceuticals-18-00247"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doolan</surname><given-names>B.J.</given-names></name>
<name><surname>Gupta</surname><given-names>M.</given-names></name>
</person-group><article-title>Melasma</article-title><source>Aust. J. Gen. Pract.</source><year>2021</year><volume>50</volume><fpage>880</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.31128/AJGP-05-21-6002</pub-id><pub-id pub-id-type="pmid">34845463</pub-id>
</element-citation></ref><ref id="B89-pharmaceuticals-18-00247"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cassiano</surname><given-names>D.P.</given-names></name>
<name><surname>Esp&#x000f3;sito</surname><given-names>A.C.C.</given-names></name>
<name><surname>Da Silva</surname><given-names>C.N.</given-names></name>
<name><surname>Lima</surname><given-names>P.B.</given-names></name>
<name><surname>Dias</surname><given-names>J.A.F.</given-names></name>
<name><surname>Hassun</surname><given-names>K.</given-names></name>
<name><surname>Miot</surname><given-names>L.D.B.</given-names></name>
<name><surname>Miot</surname><given-names>H.A.</given-names></name>
<name><surname>Bagatin</surname><given-names>E.</given-names></name>
</person-group><article-title>Update on Melasma&#x02014;Part II: Treatment</article-title><source>Dermatol. Ther.</source><year>2022</year><volume>12</volume><fpage>1989</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1007/s13555-022-00780-4</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-18-00247"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Xia</surname><given-names>Y.</given-names></name>
</person-group><article-title>New Mechanistic Insights of Melasma</article-title><source>Clin. Cosmet. Investig. Dermatol.</source><year>2023</year><volume>16</volume><fpage>429</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.2147/CCID.S396272</pub-id><pub-id pub-id-type="pmid">36817641</pub-id>
</element-citation></ref><ref id="B91-pharmaceuticals-18-00247"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bs</surname><given-names>K.M.B.</given-names></name>
<name><surname>Babbush</surname><given-names>R.A.</given-names></name>
<name><surname>Khachemoune</surname><given-names>A.</given-names></name>
</person-group><article-title>Treatment of melasma: A review of less commonly used antioxidants</article-title><source>Int. J. Dermatol.</source><year>2021</year><volume>60</volume><fpage>166</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1111/ijd.15133</pub-id><pub-id pub-id-type="pmid">32815582</pub-id>
</element-citation></ref><ref id="B92-pharmaceuticals-18-00247"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>AlSalem</surname><given-names>S.</given-names></name>
<name><surname>Alexis</surname><given-names>A.</given-names></name>
</person-group><article-title>Melasma hyperpigmentation: An overview of current topical therapeutics</article-title><source>Dermatol. Rev.</source><year>2022</year><volume>4</volume><fpage>38</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/der2.152</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-18-00247"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>T.H.</given-names></name>
<name><surname>Kim</surname><given-names>W.I.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Cho</surname><given-names>M.K.</given-names></name>
</person-group><article-title>The effects of green tea on acne vulgaris: A systematic review and meta-analysis of randomized clinical trials</article-title><source>Phytother. Res.</source><year>2020</year><volume>35</volume><fpage>374</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1002/ptr.6809</pub-id><pub-id pub-id-type="pmid">32812270</pub-id>
</element-citation></ref><ref id="B94-pharmaceuticals-18-00247"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waranuch</surname><given-names>N.</given-names></name>
<name><surname>Phimnuan</surname><given-names>P.</given-names></name>
<name><surname>Yakaew</surname><given-names>S.</given-names></name>
<name><surname>Nakyai</surname><given-names>W.</given-names></name>
<name><surname>Grandmottet</surname><given-names>F.</given-names></name>
<name><surname>Onlom</surname><given-names>C.</given-names></name>
<name><surname>Srivilai</surname><given-names>J.</given-names></name>
<name><surname>Viyoch</surname><given-names>J.</given-names></name>
</person-group><article-title>Antiacne and antiblotch activities of a formulated combination of Aloe barbadensis leaf powder, Garcinia mangostana peel extract, and Camellia sinensis leaf extract</article-title><source>Clin. Cosmet. Investig. Dermatol.</source><year>2019</year><volume>12</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.2147/CCID.S200564</pub-id><pub-id pub-id-type="pmid">31239743</pub-id>
</element-citation></ref><ref id="B95-pharmaceuticals-18-00247"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikeda</surname><given-names>S.</given-names></name>
<name><surname>Kanoya</surname><given-names>Y.</given-names></name>
<name><surname>Nagata</surname><given-names>S.</given-names></name>
</person-group><article-title>Effects of a foot bath containing green tea polyphenols on interdigital tinea pedis</article-title><source>Foot</source><year>2013</year><volume>23</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.foot.2013.01.001</pub-id><pub-id pub-id-type="pmid">23499394</pub-id>
</element-citation></ref><ref id="B96-pharmaceuticals-18-00247"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loing</surname><given-names>E.</given-names></name>
<name><surname>Lachance</surname><given-names>R.</given-names></name>
<name><surname>Ollier</surname><given-names>V.</given-names></name>
<name><surname>Hocquaux</surname><given-names>M.</given-names></name>
</person-group><article-title>A new strategy to modulate alopecia using a combination of two specific and unique ingredients</article-title><source>J. Cosmet. Sci.</source><year>2013</year><volume>64</volume><fpage>45</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">23449130</pub-id>
</element-citation></ref><ref id="B97-pharmaceuticals-18-00247"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>T.</given-names></name>
<name><surname>Kamimura</surname><given-names>A.</given-names></name>
<name><surname>Kagoura</surname><given-names>M.</given-names></name>
<name><surname>Toyoda</surname><given-names>M.</given-names></name>
<name><surname>Morohashi</surname><given-names>M.</given-names></name>
</person-group><article-title>Investigation of the topical application of procyanidin oligomers from apples to identify their potential use as a hair-growing agent</article-title><source>J. Cosmet. Dermatol.</source><year>2005</year><volume>4</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1111/j.1473-2165.2005.00199.x</pub-id><pub-id pub-id-type="pmid">17168871</pub-id>
</element-citation></ref><ref id="B98-pharmaceuticals-18-00247"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehrbani</surname><given-names>M.</given-names></name>
<name><surname>Choopani</surname><given-names>R.</given-names></name>
<name><surname>Fekri</surname><given-names>A.</given-names></name>
<name><surname>Mehrabani</surname><given-names>M.</given-names></name>
<name><surname>Mosaddegh</surname><given-names>M.</given-names></name>
<name><surname>Mehrabani</surname><given-names>M.</given-names></name>
</person-group><article-title>The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial</article-title><source>J. Ethnopharmacol.</source><year>2015</year><volume>172</volume><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2015.07.003</pub-id><pub-id pub-id-type="pmid">26151244</pub-id>
</element-citation></ref><ref id="B99-pharmaceuticals-18-00247"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Kong</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>He</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients with Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial</article-title><source>JAMA Dermatol.</source><year>2022</year><volume>158</volume><fpage>779</fpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2022.1736</pub-id><pub-id pub-id-type="pmid">35648426</pub-id>
</element-citation></ref><ref id="B100-pharmaceuticals-18-00247"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharquie</surname><given-names>K.E.</given-names></name>
<name><surname>Noaimi</surname><given-names>A.A.</given-names></name>
<name><surname>Al-Salih</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Topical therapy of acne vulgaris using 2% tea lotion in comparison with 5% zinc sulphate solution</article-title><source>Saudi Med. J.</source><year>2008</year><volume>29</volume><fpage>1757</fpage><lpage>1761</lpage><pub-id pub-id-type="pmid">19082228</pub-id>
</element-citation></ref><ref id="B101-pharmaceuticals-18-00247"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharquie</surname><given-names>K.E.</given-names></name>
<name><surname>Al-Turfi</surname><given-names>I.A.</given-names></name>
<name><surname>Al-Shimary</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Treatment of acne vulgaris with 2% topical tea lotion</article-title><source>Saudi Med. J.</source><year>2006</year><volume>27</volume><fpage>83</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">16432600</pub-id>
</element-citation></ref><ref id="B102-pharmaceuticals-18-00247"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elsaie</surname><given-names>M.L.</given-names></name>
<name><surname>Abdelhamid</surname><given-names>M.F.</given-names></name>
<name><surname>Elsaaiee</surname><given-names>L.T.</given-names></name>
<name><surname>Emam</surname><given-names>H.M.</given-names></name>
</person-group><article-title>The efficacy of topical 2% green tea lotion in mild-to-moderate acne vulgaris</article-title><source>J. Drugs Dermatol.</source><year>2009</year><volume>8</volume><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">19363854</pub-id>
</element-citation></ref><ref id="B103-pharmaceuticals-18-00247"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmood</surname><given-names>T.</given-names></name>
<name><surname>Akhtar</surname><given-names>N.</given-names></name>
<name><surname>Khan</surname><given-names>B.A.</given-names></name>
<name><surname>Khan</surname><given-names>H.M.S.</given-names></name>
<name><surname>Saeed</surname><given-names>T.</given-names></name>
</person-group><article-title>Outcomes of 3% green tea emulsion on skin sebum production in male volunteers</article-title><source>Bosn. J. Basic Med. Sci.</source><year>2010</year><volume>10</volume><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.17305/bjbms.2010.2697</pub-id><pub-id pub-id-type="pmid">20846135</pub-id>
</element-citation></ref><ref id="B104-pharmaceuticals-18-00247"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>M.K.</given-names></name>
<name><surname>Ha</surname><given-names>S.</given-names></name>
<name><surname>Son</surname><given-names>J.-A.</given-names></name>
<name><surname>Song</surname><given-names>J.H.</given-names></name>
<name><surname>Houh</surname><given-names>Y.</given-names></name>
<name><surname>Cho</surname><given-names>E.</given-names></name>
<name><surname>Chun</surname><given-names>J.H.</given-names></name>
<name><surname>Yoon</surname><given-names>S.R.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Ban</surname><given-names>S.I.</given-names></name>
<etal/>
</person-group><article-title>Polyphenon-60 displays a therapeutic effect on acne by suppression of TLR2 and IL-8 expression via down-regulating the ERK1/2 pathway</article-title><source>Arch. Dermatol. Res.</source><year>2012</year><volume>304</volume><fpage>655</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1007/s00403-012-1249-x</pub-id><pub-id pub-id-type="pmid">22684779</pub-id>
</element-citation></ref><ref id="B105-pharmaceuticals-18-00247"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>J.Y.</given-names></name>
<name><surname>Kwon</surname><given-names>H.H.</given-names></name>
<name><surname>Min</surname><given-names>S.U.</given-names></name>
<name><surname>Thiboutot</surname><given-names>D.M.</given-names></name>
<name><surname>Suh</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting <italic toggle="yes">P. acnes</italic></article-title><source>J. Investig. Dermatol.</source><year>2013</year><volume>133</volume><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.292</pub-id><pub-id pub-id-type="pmid">23096708</pub-id>
</element-citation></ref><ref id="B106-pharmaceuticals-18-00247"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>P.</given-names></name>
<name><surname>Hsu</surname><given-names>C.</given-names></name>
</person-group><article-title>Does supplementation with green tea extract improve acne in post-adolescent women? A randomized, double-blind, and placebo-controlled clinical trial</article-title><source>Complement. Ther. Med.</source><year>2016</year><volume>25</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.ctim.2016.03.004</pub-id><pub-id pub-id-type="pmid">27062963</pub-id>
</element-citation></ref><ref id="B107-pharmaceuticals-18-00247"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmood</surname><given-names>T.</given-names></name>
<name><surname>Akhtar</surname><given-names>N.</given-names></name>
<name><surname>Moldovan</surname><given-names>C.</given-names></name>
</person-group><article-title>A comparison of the effects of topical green tea and lotus on facial sebum control in healthy humans</article-title><source>Hippokratia</source><year>2013</year><volume>17</volume><fpage>64</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">23935347</pub-id>
</element-citation></ref><ref id="B108-pharmaceuticals-18-00247"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seok</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>T.S.</given-names></name>
<name><surname>Kwon</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>S.P.</given-names></name>
<name><surname>Kang</surname><given-names>M.H.</given-names></name>
<name><surname>Kim</surname><given-names>B.J.</given-names></name>
<name><surname>Kim</surname><given-names>M.N.</given-names></name>
</person-group><article-title>Efficacy of <italic toggle="yes">Cistanche Tubulosa</italic> and <italic toggle="yes">Laminaria Japonica</italic> Extracts (MK-R7) Supplement in Preventing Patterned Hair Loss and Promoting Scalp Health</article-title><source>Clin. Nutr. Res.</source><year>2015</year><volume>4</volume><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.7762/cnr.2015.4.2.124</pub-id><pub-id pub-id-type="pmid">25954733</pub-id>
</element-citation></ref><ref id="B109-pharmaceuticals-18-00247"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamimura</surname><given-names>A.</given-names></name>
<name><surname>Takahashi</surname><given-names>T.</given-names></name>
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
</person-group><article-title>Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair growing agent</article-title><source>Phytomedicine</source><year>2000</year><volume>7</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/S0944-7113(00)80040-9</pub-id><pub-id pub-id-type="pmid">11194183</pub-id>
</element-citation></ref><ref id="B110-pharmaceuticals-18-00247"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>B.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Joshi</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Topical Treatment of Dermatophytic Lesion on Mice (<italic toggle="yes">Mus musculus</italic>) Model</article-title><source>Indian J. Microbiol.</source><year>2011</year><volume>51</volume><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1007/s12088-011-0109-2</pub-id><pub-id pub-id-type="pmid">22654168</pub-id>
</element-citation></ref><ref id="B111-pharmaceuticals-18-00247"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romero-Cerecero</surname><given-names>O.</given-names></name>
<name><surname>Rojas</surname><given-names>G.</given-names></name>
<name><surname>Navarro</surname><given-names>V.</given-names></name>
<name><surname>Herrera-Arellano</surname><given-names>A.</given-names></name>
<name><surname>Zamilpa-&#x000c1;lvarez</surname><given-names>A.</given-names></name>
<name><surname>Tortoriello</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness and tolerability of a standardized extract from <italic toggle="yes">Ageratina pichinchensis</italic> on patients with tinea pedis: An explorative pilot study controlled with ketoconazole</article-title><source>Planta Medica</source><year>2006</year><volume>72</volume><fpage>1257</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1055/s-2006-951694</pub-id><pub-id pub-id-type="pmid">17051456</pub-id>
</element-citation></ref><ref id="B112-pharmaceuticals-18-00247"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herrera-Arellano</surname><given-names>A.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Soberanes</surname><given-names>A.</given-names></name>
<name><surname>de los Angeles Mart&#x000ed;nez-Rivera</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;nez-Cruz</surname><given-names>E.</given-names></name>
<name><surname>Zamilpa</surname><given-names>A.</given-names></name>
<name><surname>Alvarez</surname><given-names>L.</given-names></name>
<name><surname>Tortoriello</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness and tolerability of a standardized phytodrug derived from <italic toggle="yes">Solanum chrysotrichum</italic> on <italic toggle="yes">Tinea pedis</italic>: A controlled and randomized clinical trial</article-title><source>Planta Med.</source><year>2003</year><volume>69</volume><fpage>390</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">12802717</pub-id>
</element-citation></ref><ref id="B113-pharmaceuticals-18-00247"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romero-Cerecero</surname><given-names>O.</given-names></name>
<name><surname>Islas-Gardu&#x000f1;o</surname><given-names>A.L.</given-names></name>
<name><surname>Zamilpa</surname><given-names>A.</given-names></name>
<name><surname>Tortoriello</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness of an encecalin standardized extract of <italic toggle="yes">Ageratina pichinchensis</italic> on the treatment of onychomycosis in patients with diabetes mellitus</article-title><source>Phytother. Res.</source><year>2020</year><volume>34</volume><fpage>1678</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1002/ptr.6644</pub-id><pub-id pub-id-type="pmid">32086985</pub-id>
</element-citation></ref><ref id="B114-pharmaceuticals-18-00247"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herrera-Arellano</surname><given-names>A.</given-names></name>
<name><surname>Jim&#x000e9;nez-Ferrer</surname><given-names>E.</given-names></name>
<name><surname>Vega-Pimentel</surname><given-names>A.M.</given-names></name>
<name><surname>de los Angeles Mart&#x000ed;nez-Rivera</surname><given-names>M.</given-names></name>
<name><surname>Hern&#x000e1;ndez-Hern&#x000e1;ndez</surname><given-names>M.</given-names></name>
<name><surname>Zamilpa</surname><given-names>A.</given-names></name>
<name><surname>Tortoriello</surname><given-names>J.</given-names></name>
</person-group><article-title>Clinical and mycological evaluation of therapeutic effectiveness of <italic toggle="yes">Solanum chrysotrichum</italic> standardized extract on patients with <italic toggle="yes">Pityriasis capitis</italic> (dandruff). A double blind and randomized clinical trial controlled with ketoconazole</article-title><source>Planta Med.</source><year>2004</year><volume>70</volume><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1055/s-2004-827145</pub-id><pub-id pub-id-type="pmid">15241887</pub-id>
</element-citation></ref><ref id="B115-pharmaceuticals-18-00247"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ngatu</surname><given-names>N.R.</given-names></name>
<name><surname>Saruta</surname><given-names>T.</given-names></name>
<name><surname>Hirota</surname><given-names>R.</given-names></name>
<name><surname>Eitoku</surname><given-names>M.</given-names></name>
<name><surname>Luzitu</surname><given-names>N.S.</given-names></name>
<name><surname>Muzembo</surname><given-names>B.A.</given-names></name>
<name><surname>Matsui</surname><given-names>T.</given-names></name>
<name><surname>Suganuma</surname><given-names>N.</given-names></name>
</person-group><article-title>Brazilian green propolis extracts improve <italic toggle="yes">Tinea pedis</italic> interdigitalis and Tinea corporis</article-title><source>J. Altern. Complement. Med.</source><year>2012</year><volume>18</volume><fpage>8</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1089/acm.2011.0696</pub-id><pub-id pub-id-type="pmid">22229708</pub-id>
</element-citation></ref><ref id="B116-pharmaceuticals-18-00247"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ngatu</surname><given-names>N.R.</given-names></name>
<name><surname>Saruta</surname><given-names>T.</given-names></name>
<name><surname>Hirota</surname><given-names>R.</given-names></name>
<name><surname>Eitoku</surname><given-names>M.</given-names></name>
<name><surname>Muzembo</surname><given-names>B.A.</given-names></name>
<name><surname>Matsui</surname><given-names>T.</given-names></name>
<name><surname>Nangana</surname><given-names>L.S.</given-names></name>
<name><surname>Mbenza</surname><given-names>M.A.</given-names></name>
<name><surname>Kumagai</surname><given-names>N.</given-names></name>
<name><surname>Suganuma</surname><given-names>N.</given-names></name>
</person-group><article-title>Antifungal efficacy of Brazilian green propolis extracts and honey on Tinea capitis and Tinea versicolor</article-title><source>Eur. J. Integr. Med.</source><year>2011</year><volume>3</volume><fpage>e281</fpage><lpage>e287</lpage><pub-id pub-id-type="doi">10.1016/j.eujim.2011.10.001</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-18-00247"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Obot</surname><given-names>M.J.</given-names></name>
<name><surname>Aluyi</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Treatment of superficial mycoses with <italic toggle="yes">Ocimum gratissimum</italic></article-title><source>Int. J. Infect. Dis.</source><year>2002</year><volume>6</volume><fpage>151</fpage><pub-id pub-id-type="doi">10.1016/S1201-9712(02)90080-9</pub-id><pub-id pub-id-type="pmid">12146502</pub-id>
</element-citation></ref><ref id="B118-pharmaceuticals-18-00247"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oyelami</surname><given-names>O.A.</given-names></name>
<name><surname>Onayemi</surname><given-names>O.</given-names></name>
<name><surname>Oladimeji</surname><given-names>F.A.</given-names></name>
<name><surname>Ogundaini</surname><given-names>A.O.</given-names></name>
<name><surname>Olugbade</surname><given-names>T.A.</given-names></name>
<name><surname>Onawunmi</surname><given-names>G.O.</given-names></name>
</person-group><article-title>Clinical evaluation of Acalypha ointment in the treatment of superficial fungal skin diseases</article-title><source>Phytother. Res.</source><year>2003</year><volume>17</volume><fpage>555</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1002/ptr.1161</pub-id><pub-id pub-id-type="pmid">12748998</pub-id>
</element-citation></ref><ref id="B119-pharmaceuticals-18-00247"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carmo</surname><given-names>E.S.</given-names></name>
<name><surname>Pereira</surname><given-names>F.d.O.</given-names></name>
<name><surname>Cavalcante</surname><given-names>N.M.</given-names></name>
<name><surname>Gayoso</surname><given-names>C.W.</given-names></name>
<name><surname>Lima</surname><given-names>E.d.O.</given-names></name>
</person-group><article-title>Treatment of pityriasis versicolor with topical application of essential oil of <italic toggle="yes">Cymbopogon citratus</italic> (DC) Stapf&#x02014;Therapeutic pilot study</article-title><source>An. Bras. Dermatol.</source><year>2013</year><volume>88</volume><fpage>381</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1590/abd1806-4841.20131800</pub-id><pub-id pub-id-type="pmid">23793205</pub-id>
</element-citation></ref><ref id="B120-pharmaceuticals-18-00247"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damodaran</surname><given-names>S.</given-names></name>
<name><surname>Venkataraman</surname><given-names>S.</given-names></name>
</person-group><article-title>A study on the therapeutic efficacy of <italic toggle="yes">Cassia alata</italic>, Linn. leaf extract against <italic toggle="yes">Pityriasis versicolor</italic></article-title><source>J. Ethnopharmacol.</source><year>1994</year><volume>42</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/0378-8741(94)90018-3</pub-id><pub-id pub-id-type="pmid">8046939</pub-id>
</element-citation></ref><ref id="B121-pharmaceuticals-18-00247"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buck</surname><given-names>D.S.</given-names></name>
<name><surname>Nidorf</surname><given-names>D.M.</given-names></name>
<name><surname>Addino</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole</article-title><source>J. Fam. Pract.</source><year>1994</year><volume>38</volume><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">8195735</pub-id>
</element-citation></ref><ref id="B122-pharmaceuticals-18-00247"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patrizi</surname><given-names>A.</given-names></name>
<name><surname>Raone</surname><given-names>B.</given-names></name>
<name><surname>Neri</surname><given-names>I.</given-names></name>
<name><surname>Gurioli</surname><given-names>C.</given-names></name>
<name><surname>Carbonara</surname><given-names>M.</given-names></name>
<name><surname>Cassano</surname><given-names>N.</given-names></name>
<name><surname>Vena</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Randomized, controlled, double-blind clinical study evaluating the safety and efficacy of MD2011001 cream in mild-to-moderate atopic dermatitis of the face and neck in children, adolescents and adults</article-title><source>J. Dermatol. Treat.</source><year>2016</year><volume>27</volume><fpage>346</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.3109/09546634.2015.1115814</pub-id><pub-id pub-id-type="pmid">26652026</pub-id>
</element-citation></ref><ref id="B123-pharmaceuticals-18-00247"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brasiel</surname><given-names>P.G.d.A.</given-names></name>
<name><surname>Guimar&#x000e3;es</surname><given-names>F.V.</given-names></name>
<name><surname>Rodrigues</surname><given-names>P.M.</given-names></name>
<name><surname>Bou-Habib</surname><given-names>D.C.</given-names></name>
<name><surname>Carvalho</surname><given-names>V.d.F.</given-names></name>
</person-group><article-title>Therapeutic Efficacy of Flavonoids in Allergies: A Systematic Review of Randomized Controlled Trials</article-title><source>J. Immunol. Res.</source><year>2022</year><volume>2022</volume><fpage>8191253</fpage><pub-id pub-id-type="doi">10.1155/2022/8191253</pub-id><pub-id pub-id-type="pmid">35465348</pub-id>
</element-citation></ref><ref id="B124-pharmaceuticals-18-00247"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Jia</surname><given-names>L.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Kong</surname><given-names>L.</given-names></name>
<name><surname>Xing</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy</article-title><source>Br. J. Radiol.</source><year>2016</year><volume>89</volume><fpage>20150665</fpage><pub-id pub-id-type="doi">10.1259/bjr.20150665</pub-id><pub-id pub-id-type="pmid">26607642</pub-id>
</element-citation></ref><ref id="B125-pharmaceuticals-18-00247"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Jia</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>P.</given-names></name>
<name><surname>Yin</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Xing</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: A phase I clinical trial</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>13865</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-40881-4</pub-id><pub-id pub-id-type="pmid">37620508</pub-id>
</element-citation></ref><ref id="B126-pharmaceuticals-18-00247"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karbasforooshan</surname><given-names>H.</given-names></name>
<name><surname>Hosseini</surname><given-names>S.</given-names></name>
<name><surname>Elyasi</surname><given-names>S.</given-names></name>
<name><surname>Pakdel</surname><given-names>A.F.</given-names></name>
<name><surname>Karimi</surname><given-names>G.</given-names></name>
</person-group><article-title>Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double-blind, placebo-controlled clinical trial</article-title><source>Phytother. Res.</source><year>2019</year><volume>33</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1002/ptr.6231</pub-id><pub-id pub-id-type="pmid">30479044</pub-id>
</element-citation></ref><ref id="B127-pharmaceuticals-18-00247"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magrone</surname><given-names>T.</given-names></name>
<name><surname>Jirillo</surname><given-names>E.</given-names></name>
<name><surname>Magrone</surname><given-names>M.</given-names></name>
<name><surname>Russo</surname><given-names>M.A.</given-names></name>
<name><surname>Romita</surname><given-names>P.</given-names></name>
<name><surname>Massari</surname><given-names>F.</given-names></name>
<name><surname>Foti</surname><given-names>C.</given-names></name>
</person-group><article-title>Red Grape Polyphenol Oral Administration Improves Immune Response in Women Affected by Nickel-Mediated Allergic Contact Dermatitis</article-title><source>Endocr. Metab. Immune Disord.-Drug Targets</source><year>2021</year><volume>21</volume><fpage>374</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.2174/1871530320666200313152648</pub-id><pub-id pub-id-type="pmid">32167433</pub-id>
</element-citation></ref><ref id="B128-pharmaceuticals-18-00247"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.</given-names></name>
<name><surname>Bonner</surname><given-names>M.Y.</given-names></name>
<name><surname>Arbiser</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Use of Polyphenolic Compounds in Dermatologic Oncology</article-title><source>Am. J. Clin. Dermatol.</source><year>2016</year><volume>17</volume><fpage>369</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s40257-016-0193-5</pub-id><pub-id pub-id-type="pmid">27164914</pub-id>
</element-citation></ref><ref id="B129-pharmaceuticals-18-00247"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.-M.</given-names></name>
<name><surname>Cheng</surname><given-names>M.-Y.</given-names></name>
<name><surname>Xun</surname><given-names>M.-H.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.-W.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
</person-group><article-title>Possible Mechanisms of Oxidative Stress-Induced Skin Cellular Senescence, Inflammation, and Cancer and the Therapeutic Potential of Plant Polyphenols</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>3755</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24043755</pub-id><pub-id pub-id-type="pmid">36835162</pub-id>
</element-citation></ref><ref id="B130-pharmaceuticals-18-00247"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trindade</surname><given-names>L.R.</given-names></name>
<name><surname>da Silva</surname><given-names>D.V.T.</given-names></name>
<name><surname>Bai&#x000e3;o</surname><given-names>D.d.S.</given-names></name>
<name><surname>Paschoalin</surname><given-names>V.M.F.</given-names></name>
</person-group><article-title>Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>4621</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26154621</pub-id><pub-id pub-id-type="pmid">34361774</pub-id>
</element-citation></ref><ref id="B131-pharmaceuticals-18-00247"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bilia</surname><given-names>A.R.</given-names></name>
<name><surname>Piazzini</surname><given-names>V.</given-names></name>
<name><surname>Risaliti</surname><given-names>L.</given-names></name>
<name><surname>Vanti</surname><given-names>G.</given-names></name>
<name><surname>Casamonti</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Bergonzi</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Nanocarriers: A Successful Tool to Increase Solubility, Stability and Optimise Bioefficacy of Natural Constituents</article-title><source>Curr. Med. Chem.</source><year>2019</year><volume>26</volume><fpage>4631</fpage><lpage>4656</lpage><pub-id pub-id-type="doi">10.2174/0929867325666181101110050</pub-id><pub-id pub-id-type="pmid">30381065</pub-id>
</element-citation></ref><ref id="B132-pharmaceuticals-18-00247"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iqubal</surname><given-names>M.K.</given-names></name>
<name><surname>Iqubal</surname><given-names>A.</given-names></name>
<name><surname>Imtiyaz</surname><given-names>K.</given-names></name>
<name><surname>Rizvi</surname><given-names>M.M.A.</given-names></name>
<name><surname>Gupta</surname><given-names>M.M.</given-names></name>
<name><surname>Ali</surname><given-names>J.</given-names></name>
<name><surname>Baboota</surname><given-names>S.</given-names></name>
</person-group><article-title>Combinatorial lipid-nanosystem for dermal delivery of 5-fluorouracil and resveratrol against skin cancer: Delineation of improved dermatokinetics and epidermal drug deposition enhancement analysis</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2021</year><volume>163</volume><fpage>223</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2021.04.007</pub-id><pub-id pub-id-type="pmid">33864904</pub-id>
</element-citation></ref><ref id="B133-pharmaceuticals-18-00247"><label>133.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Menaa</surname><given-names>F.</given-names></name>
<name><surname>Menaa</surname><given-names>A.</given-names></name>
<name><surname>Menaa</surname><given-names>B.</given-names></name>
</person-group><article-title>Polyphenols Nano-Formulations for Topical Delivery and Skin Tissue Engineering</article-title><source>Polyphenols in Human Health and Disease</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2014</year><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-398456-2.00065-7</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-18-00247"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qadir</surname><given-names>A.</given-names></name>
<name><surname>Aqil</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Warsi</surname><given-names>M.H.</given-names></name>
<name><surname>Mujeeb</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>F.J.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Beg</surname><given-names>S.</given-names></name>
</person-group><article-title>Nanostructured lipidic carriers for dual drug delivery in the management of psoriasis: Systematic optimization, dermatokinetic and preclinical evaluation</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>57</volume><fpage>101775</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2020.101775</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-18-00247"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasan</surname><given-names>N.</given-names></name>
<name><surname>Imran</surname><given-names>M.</given-names></name>
<name><surname>Nadeem</surname><given-names>M.</given-names></name>
<name><surname>Jain</surname><given-names>D.</given-names></name>
<name><surname>Haider</surname><given-names>K.</given-names></name>
<name><surname>Alam Rizvi</surname><given-names>M.M.</given-names></name>
<name><surname>Sheikh</surname><given-names>A.</given-names></name>
<name><surname>Kesharwani</surname><given-names>P.</given-names></name>
<name><surname>Jain</surname><given-names>G.K.</given-names></name>
<name><surname>Ahmad</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>632</volume><fpage>122580</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122580</pub-id><pub-id pub-id-type="pmid">36608807</pub-id>
</element-citation></ref><ref id="B136-pharmaceuticals-18-00247"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.K.</given-names></name>
<name><surname>Dixit</surname><given-names>V.K.</given-names></name>
</person-group><article-title>Development and evaluation of vesicular system for curcumin delivery</article-title><source>Arch. Dermatol. Res.</source><year>2011</year><volume>303</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s00403-010-1096-6</pub-id><pub-id pub-id-type="pmid">21085975</pub-id>
</element-citation></ref><ref id="B137-pharmaceuticals-18-00247"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trepa</surname><given-names>M.</given-names></name>
<name><surname>Su&#x00142;kowska-Ziaja</surname><given-names>K.</given-names></name>
<name><surname>Ka&#x00142;a</surname><given-names>K.</given-names></name>
<name><surname>Muszy&#x00144;ska</surname><given-names>B.</given-names></name>
</person-group><article-title>Therapeutic Potential of Fungal Terpenes and Terpenoids: Application in Skin Diseases</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>1183</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29051183</pub-id><pub-id pub-id-type="pmid">38474692</pub-id>
</element-citation></ref><ref id="B138-pharmaceuticals-18-00247"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stevanovi&#x00107;</surname><given-names>Z.D.</given-names></name>
<name><surname>Aligiannis</surname><given-names>N.</given-names></name>
<name><surname>Graikou</surname><given-names>K.</given-names></name>
<name><surname>Bilia</surname><given-names>A.R.</given-names></name>
<name><surname>Kola&#x00161;inac</surname><given-names>S.</given-names></name>
<name><surname>Kilibarda</surname><given-names>S.</given-names></name>
</person-group><article-title>Bioactivity of carotenoids and their role in skin disorders: From tradition to application</article-title><source>Maced. Pharm. Bull.</source><year>2022</year><volume>68</volume><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.33320/maced.pharm.bull.2022.68.04.067</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-18-00247"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maurya</surname><given-names>S.K.</given-names></name>
<name><surname>Divakar</surname><given-names>S.</given-names></name>
<name><surname>Patil</surname><given-names>U.K.</given-names></name>
</person-group><article-title>Potentials of plant derived products for the treatment of skin disorders</article-title><source>Ger. J. Pharm. Biomater.</source><year>2023</year><volume>2</volume><fpage>9</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.5530/gjpb.2023.3.8</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-18-00247"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.M.N.</given-names></name>
<name><surname>Park</surname><given-names>H.-A.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.T.T.</given-names></name>
<name><surname>Lee</surname><given-names>N.-Y.</given-names></name>
<name><surname>Ban</surname><given-names>S.-Y.</given-names></name>
<name><surname>Park</surname><given-names>K.-B.</given-names></name>
<name><surname>Lee</surname><given-names>C.-K.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>J.-T.</given-names></name>
</person-group><article-title>Protective Effects of Lanostane Triterpenoids from Chaga Mushroom in Human Keratinocytes, HaCaT Cells, against Inflammatory and Oxidative Stresses</article-title><source>IJMS</source><year>2023</year><volume>24</volume><elocation-id>12803</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241612803</pub-id><pub-id pub-id-type="pmid">37628993</pub-id>
</element-citation></ref><ref id="B141-pharmaceuticals-18-00247"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>Z.F.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>F.H.</given-names></name>
<name><surname>Mao</surname><given-names>X.X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>C.T.</given-names></name>
</person-group><article-title>Inhibitory and Acceleratory Effects of <italic toggle="yes">Inonotus obliquus</italic> on Tyrosinase Activity and Melanin Formation in B16 Melanoma Cells</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2014</year><volume>2014</volume><fpage>259836</fpage><pub-id pub-id-type="doi">10.1155/2014/259836</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-18-00247"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kreuzenbeck</surname><given-names>N.B.</given-names></name>
<name><surname>Dhiman</surname><given-names>S.</given-names></name>
<name><surname>Roman</surname><given-names>D.</given-names></name>
<name><surname>Burkhardt</surname><given-names>I.</given-names></name>
<name><surname>Conlon</surname><given-names>B.H.</given-names></name>
<name><surname>Fricke</surname><given-names>J.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Blume</surname><given-names>J.</given-names></name>
<name><surname>G&#x000f6;rls</surname><given-names>H.</given-names></name>
<name><surname>Poulsen</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Isolation, (bio)synthetic studies and evaluation of antimicrobial properties of drimenol-type sesquiterpenes of <italic toggle="yes">Termitomyces</italic> fungi</article-title><source>Commun. Chem.</source><year>2023</year><volume>6</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1038/s42004-023-00871-z</pub-id><pub-id pub-id-type="pmid">37095327</pub-id>
</element-citation></ref><ref id="B143-pharmaceuticals-18-00247"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Ganoderma lucidum: A rational pharmacological approach to surmount cancer</article-title><source>J. Ethnopharmacol.</source><year>2020</year><volume>260</volume><fpage>113047</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2020.113047</pub-id><pub-id pub-id-type="pmid">32504783</pub-id>
</element-citation></ref><ref id="B144-pharmaceuticals-18-00247"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>Q.</given-names></name>
<name><surname>Lu</surname><given-names>X.-Y.</given-names></name>
<name><surname>Han</surname><given-names>J.-X.</given-names></name>
<name><surname>Aisa</surname><given-names>H.A.</given-names></name>
<name><surname>Yuan</surname><given-names>T.</given-names></name>
</person-group><article-title>Triterpenoids and phenolics from the fruiting bodies of <italic toggle="yes">Inonotus hispidus</italic> and their activations of melanogenesis and tyrosinase</article-title><source>Chin. Chem. Lett.</source><year>2017</year><volume>28</volume><fpage>1052</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/j.cclet.2016.12.010</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-18-00247"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darvin</surname><given-names>M.E.</given-names></name>
<name><surname>Sterry</surname><given-names>W.</given-names></name>
<name><surname>Lademann</surname><given-names>J.</given-names></name>
<name><surname>Vergou</surname><given-names>T.</given-names></name>
</person-group><article-title>The Role of Carotenoids in Human Skin</article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>10491</fpage><lpage>10506</lpage><pub-id pub-id-type="doi">10.3390/molecules161210491</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-18-00247"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>I Ibiebele</surname><given-names>T.</given-names></name>
<name><surname>van der Pols</surname><given-names>J.C.</given-names></name>
<name><surname>Hughes</surname><given-names>M.C.</given-names></name>
<name><surname>Marks</surname><given-names>G.C.</given-names></name>
<name><surname>Williams</surname><given-names>G.M.</given-names></name>
<name><surname>Green</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Dietary pattern in association with squamous cell carcinoma of the skin: A prospective study</article-title><source>Am. J. Clin. Nutr.</source><year>2007</year><volume>85</volume><fpage>1401</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1093/ajcn/85.5.1401</pub-id><pub-id pub-id-type="pmid">17490979</pub-id>
</element-citation></ref><ref id="B147-pharmaceuticals-18-00247"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fortes</surname><given-names>C.</given-names></name>
<name><surname>Mastroeni</surname><given-names>S.</given-names></name>
<name><surname>Melchi</surname><given-names>F.</given-names></name>
<name><surname>A Pilla</surname><given-names>M.</given-names></name>
<name><surname>Antonelli</surname><given-names>G.</given-names></name>
<name><surname>Camaioni</surname><given-names>D.</given-names></name>
<name><surname>Alotto</surname><given-names>M.</given-names></name>
<name><surname>Pasquini</surname><given-names>P.</given-names></name>
</person-group><article-title>A protective effect of the Mediterranean diet for cutaneous melanoma</article-title><source>Leuk. Res.</source><year>2008</year><volume>37</volume><fpage>1018</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1093/ije/dyn132</pub-id></element-citation></ref><ref id="B148-pharmaceuticals-18-00247"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heinen</surname><given-names>M.M.</given-names></name>
<name><surname>Hughes</surname><given-names>M.C.</given-names></name>
<name><surname>Ibiebele</surname><given-names>T.I.</given-names></name>
<name><surname>Marks</surname><given-names>G.C.</given-names></name>
<name><surname>Green</surname><given-names>A.C.</given-names></name>
<name><surname>van der Pols</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Intake of antioxidant nutrients and the risk of skin cancer</article-title><source>Eur. J. Cancer</source><year>2007</year><volume>43</volume><fpage>2707</fpage><lpage>2716</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.09.005</pub-id><pub-id pub-id-type="pmid">17988857</pub-id>
</element-citation></ref><ref id="B149-pharmaceuticals-18-00247"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palombo</surname><given-names>P.</given-names></name>
<name><surname>Fabrizi</surname><given-names>G.</given-names></name>
<name><surname>Ruocco</surname><given-names>V.</given-names></name>
<name><surname>Ruocco</surname><given-names>E.</given-names></name>
<name><surname>Fluhr</surname><given-names>J.</given-names></name>
<name><surname>Roberts</surname><given-names>R.</given-names></name>
<name><surname>Morganti</surname><given-names>P.</given-names></name>
</person-group><article-title>Beneficial Long-Term Effects of Combined Oral/Topical Antioxidant Treatment with the Carotenoids Lutein and Zeaxanthin on Human Skin: A Double-Blind, Placebo-Controlled Study</article-title><source>Ski. Pharmacol. Physiol.</source><year>2007</year><volume>20</volume><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1159/000101807</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-18-00247"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heinrich</surname><given-names>U.</given-names></name>
<name><surname>Wiebusch</surname><given-names>M.</given-names></name>
<name><surname>Tronnier</surname><given-names>H.</given-names></name>
<name><surname>G&#x000e4;rtner</surname><given-names>C.</given-names></name>
<name><surname>Eichler</surname><given-names>O.</given-names></name>
<name><surname>Sies</surname><given-names>H.</given-names></name>
<name><surname>Stahl</surname><given-names>W.</given-names></name>
</person-group><article-title>Supplementation with &#x003b2;-Carotene or a Similar Amount of Mixed Carotenoids Protects Humans from UV-Induced Erythema</article-title><source>J. Nutr.</source><year>2003</year><volume>133</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1093/jn/133.1.98</pub-id><pub-id pub-id-type="pmid">12514275</pub-id>
</element-citation></ref><ref id="B151-pharmaceuticals-18-00247"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biskanaki</surname><given-names>F.</given-names></name>
<name><surname>Kalofiri</surname><given-names>P.</given-names></name>
<name><surname>Tertipi</surname><given-names>N.</given-names></name>
<name><surname>Sfyri</surname><given-names>E.</given-names></name>
<name><surname>Andreou</surname><given-names>E.</given-names></name>
<name><surname>Kefala</surname><given-names>V.</given-names></name>
<name><surname>Rallis</surname><given-names>E.</given-names></name>
</person-group><article-title>Carotenoids and Dermoaesthetic Benefits: Public Health Implications</article-title><source>Cosmetics</source><year>2023</year><volume>10</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.3390/cosmetics10050120</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-18-00247"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wr&#x000f3;bel-Biedrawa</surname><given-names>D.</given-names></name>
<name><surname>Grabowska</surname><given-names>K.</given-names></name>
<name><surname>Galanty</surname><given-names>A.</given-names></name>
<name><surname>Sobolewska</surname><given-names>D.</given-names></name>
<name><surname>&#x0017b;mudzki</surname><given-names>P.</given-names></name>
<name><surname>Podolak</surname><given-names>I.</given-names></name>
</person-group><article-title>Anti-melanoma potential of two benzoquinone homologues embelin and rapanone&#x02014;A comparative in vitro study</article-title><source>Toxicol. In Vitro</source><year>2020</year><volume>65</volume><fpage>104826</fpage><pub-id pub-id-type="doi">10.1016/j.tiv.2020.104826</pub-id><pub-id pub-id-type="pmid">32169436</pub-id>
</element-citation></ref><ref id="B153-pharmaceuticals-18-00247"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babu</surname><given-names>A.</given-names></name>
<name><surname>Laila</surname><given-names>S.P.</given-names></name>
<name><surname>Fernandez</surname><given-names>A.</given-names></name>
</person-group><article-title>A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma</article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2021</year><volume>21</volume><fpage>2066</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.2174/1871520621666201229115253</pub-id><pub-id pub-id-type="pmid">33372883</pub-id>
</element-citation></ref><ref id="B154-pharmaceuticals-18-00247"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamath</surname><given-names>A.J.</given-names></name>
<name><surname>Chandy</surname><given-names>A.S.</given-names></name>
<name><surname>Joseph</surname><given-names>A.A.</given-names></name>
<name><surname>Gorantla</surname><given-names>J.N.</given-names></name>
<name><surname>Donadkar</surname><given-names>A.D.</given-names></name>
<name><surname>Nath</surname><given-names>L.R.</given-names></name>
<name><surname>Sharifi-Rad</surname><given-names>J.</given-names></name>
<name><surname>Calina</surname><given-names>D.</given-names></name>
</person-group><article-title>Embelin: A multifaceted anticancer agent with translational potential in targeting tumor progression and metastasis</article-title><source>EXCLI J.</source><year>2023</year><volume>22</volume><fpage>1311</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.17179/excli2023-6590</pub-id><pub-id pub-id-type="pmid">38234968</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00247-f001"><label>Figure 1</label><caption><p>Pharmacotherapeutic mechanisms of polyphenols in skin disorders: Currently, multiple pharmacological mechanisms have been attributed to naturally occurring polyphenols for different skin pathologies, including (<bold>A</bold>) <italic toggle="yes">Acne vulgaris</italic>, where the actions of gallotannin and ellagitannin suppressed sebum production via 5&#x003b1;AR-1 inhibition. Moreover, phloretin&#x02019;s anti-inflammatory properties inhibit TLR2/1 heterodimerization and JNK signaling in human keratinocytes. Phenolic acid, myricetin, quercetin, and luteolin can inhibit MMP-9 and, thus, diminish acne lesions and, in addition, have similar effects to rosmarinic acid, apigenin, and carvacrol over NF-kB by blocking the molecule and decreasing the subsequent IL-8, II,-1B, and TNF&#x003b1; secretion; (<bold>B</bold>) the anti-inflammatory effect of polyphenols is observed in dermatitis where diosmetin, quercetin, and gallatannin inhibit signaling pathways such as ERK, JNK, and p38, as well as NK-kB translocation to the nucleus. Likewise, flavonoids such as taxifolin, aromadendrin, padmatin, and chamaejasmine were linked to IgE decrements. Resveratrol and troxerutin decrease TSLP expression, and this effect is likely associated with the IL-1&#x003b1; pathway. Quercetin has been associated with <italic toggle="yes">&#x003b2;</italic>-hexosaminidase inhibition. (<bold>C</bold>) Skin cancer is linked to ROS overproduction, DNA damage, and UV ray effects. Certain polyphenols such as catechin, epicatechin, procyanidin, quercetin, resveratrol, and piceatannol have demonstrated antioxidant properties by diminishing ROS levels. On the other hand, resveratrol and epigenin possess antitumoral activity through direct or indirect mTOR blockade. A similar effect is observed by inhibiting TLR4 through TP. Punicalagin and urolithin A repair DNA damage induced by UV rays via SIRT1 stimulation. (<bold>D</bold>) Regarding alopecia, morroniside and baicalein induce cellular proliferation as well as migration through the Wnt/&#x003b2; catenin pathway. Furthermore, fisetin and resveratrol promote &#x003b2;-catenin translocation and higher IGF-1 and KGF expression through a TERT-dependent mechanism. Lastly, polyphenols such as hesperetin and naringenin stimulated VEGF expression and proliferation in DPCs. Simultaneously, this molecule promotes PDGF and EGF increments, inhibiting the DHT effect on androgenic receptors. Similarly, TSG diminishes DPC apoptosis via Bcl-2/BAD blockade. Abbreviations: TLR: Toll-like receptor; JNK: Jun N-terminal kinase; 5&#x003b1;AR-1: 5-alpha reductase; MMP-9: Matrix Metallopeptidase 9; NF-KB: Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells; MAPK: Mitogen-Activated Protein Kinase; ERK: Extracellular-regulated Kinase; IL: Interleukin; TNF&#x003b1;: Tumor Necrosis Factor Alpha; IgE: Immunoglobulin E; TSLP: Thymic Stromal Lymphopoietin; TERT: telomerase reverse transcriptase; TSG: 2,3,5,4&#x02032;-tetrahydroxyestilbene-2-<italic toggle="yes">O</italic>-&#x003b2;-<sc>d</sc>-glucoside; PDGF: Platelet-derived Growth Factor; VEGF: Vascular Endothelial Growth Factor; EGF: Epidermal Growth Factor; DHT: Dihydrotestosterone; BAD: BCL 2-associated agonist of cell death; BCL: B-cell Lymphoma; IGF: insulin-like growth factor; KGF: keratinocyte growth factor; ROS: reactive oxygen species; TP: tea polyphenol; PI3K: Phosphoinositide 3-Kinase; AKT: Protein Kinase B; mTOR: The Mechanistic Target of Rapamycin; UVB: ultraviolet B; CPD: cyclobutane pyrimidine dimer; SIRT: Sirtuin.</p></caption><graphic xlink:href="pharmaceuticals-18-00247-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00247-f002"><label>Figure 2</label><caption><p>Underlying mechanisms of polyphenols in rosacea and melasma: The pathophysiological basis of rosacea is not completely understood; however, multiple triggers have been identified; among these are the overexposure to the acarus <italic toggle="yes">Demodex folliculorum</italic>, extreme temperatures, UV light exposure, and the consumption of alcohol and spicy foods. All of these elements can promote abnormal responses on the immune system, conditioning a pro-inflammatory state on the skin, characterized by NF-kB expression, pro-inflammatory cytokine secretion, and increased oxidative stress within the cells. It has been observed that polyphenols such as EGCG, resveratrol, and proanthocyanidins may interfere with the inflammatory response of these patients, inhibiting NF-kB expression, pro-inflammatory cytokine secretion, and Cox and Lox activation. Furthermore, because of their antioxidant activities, polyphenols are able to reduce oxidative stress levels. Likewise, polyphenols seem to improve melasma, and this condition is characterized by skin hyperpigmentation and is associated with genes such as MCR1 and ASIP, due to the activation of melanocytes by various factors like UV light and hormones (estrogen and progesterone) in pregnant women and menopausal women receiving hormone therapy. The potential protective mechanisms of polyphenols in melasma are oxidative stress reduction, inflammatory pathways&#x02019; downregulation, and potential tyrosinase inhibition. Abbreviations: COX: cyclooxygenase; LOX: lipoxygenase; NF-kB: Nuclear Factor Kappa-B; TYR: Tyrosine; UV: ultraviolet; EGCG: epigallocatechin gallate.</p></caption><graphic xlink:href="pharmaceuticals-18-00247-g002" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00247-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00247-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of key clinical evidence regarding polyphenols and skin disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Skin Disorder</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Methodology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kim et al. [<xref rid="B93-pharmaceuticals-18-00247" ref-type="bibr">93</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acne vulgaris</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meta-analysis with five randomized controlled clinical trials evaluated the efficacy and safety of green tea extract for treating acne.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Green tea extract significantly reduced the number of inflammatory lesions (&#x02212;9.38; 95% CI: &#x02212;14.13 to &#x02212;4.63), inflammatory lesion counts (&#x02212;11.39; 95% CI: &#x02212;15.91 to &#x02212;6.86), and non-inflammatory acne lesions (&#x02212;32.44; 95% CI: &#x02212;39.27 to &#x02212;25.62).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Waranuch et al. [<xref rid="B94-pharmaceuticals-18-00247" ref-type="bibr">94</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acne vulgaris</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A single-center, parallel, randomized controlled trial assessed the anti-acne and anti-blotch activity of a hydrogel formulated with a combination of <italic toggle="yes">Aloe barbadensis</italic> leaf extract and <italic toggle="yes">Garcinia mangostana</italic> peel extract.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There was a reduction in total acne lesions (<italic toggle="yes">p</italic> &#x0003c; 0.0001) and mean acne severity index. Also, a decrease in skin redness (<italic toggle="yes">p</italic> &#x0003c; 0.05) and in mean melanin value (<italic toggle="yes">p</italic> = 0.037) was found.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ikeda et al. [<xref rid="B95-pharmaceuticals-18-00247" ref-type="bibr">95</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin fungal infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A double-blind, randomized, placebo-controlled trial evaluating the effects of a foot bath containing green tea polyphenols in patients with interdigital tinea pedis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The use of a foot bath containing green tea polyphenols for 12 weeks produced a significant reduction in the size of the affected area (<italic toggle="yes">p</italic> &#x0003c; 0.001).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Loing et al. [<xref rid="B96-pharmaceuticals-18-00247" ref-type="bibr">96</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alopecia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A randomized, placebo-controlled study assessed the efficacy of <italic toggle="yes">Trifolium pratense</italic> flower extract and a biomimetic peptide in alopecia.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The anagen/telogen (A/T) ratio increased by +46%, anagen hair increased at an average of +13%, and telogen hair density decreased by &#x02212;29% after 4 months of treatment.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Takahashi et al. [<xref rid="B97-pharmaceuticals-18-00247" ref-type="bibr">97</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alopecia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A double-blind, randomized, placebo-controlled trial evaluated the efficacy of the external application of 0.7% apple procyanidin oligomers in patients with pattern baldness.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There was a significant increase in total number of hair (procyanidin, 3.3 &#x000b1; 13.0 (mean &#x000b1; SD)/0.50 cm<sup>2</sup>; placebo, &#x02212;3.6 &#x000b1; 8.1/0.50 cm<sup>2</sup>; <italic toggle="yes">p</italic> &#x0003c; 0.001, two-sample <italic toggle="yes">t</italic>-test).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mehrbani et al. [<xref rid="B98-pharmaceuticals-18-00247" ref-type="bibr">98</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atopic Dermatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A double-blind, randomized, placebo, controlled trial assessed the effect of powdered lyophilized milk serum with cuscuta extract to treat AD.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A marked increase in skin humidity and elasticity was observed (<italic toggle="yes">p</italic> &#x0003c; 0.001), along with diminished pruritus (<italic toggle="yes">p</italic> &#x0003c; 0.05) and sleep disturbances (<italic toggle="yes">p</italic> &#x0003c; 0.05).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhao et al. [<xref rid="B99-pharmaceuticals-18-00247" ref-type="bibr">99</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Radiation Dermatitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A phase II, double-blind, randomized, controlled clinical trial was performed to determine the therapeutic and preventive properties of EGCG on RD patients with breast cancer treated with post-operatory radiotherapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGCG significantly reduced the incidence, severity, and clinical manifestations of RD.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: A/T: anagen/telogen; AD: atopic dermatitis; RD: radiation dermatitis; EGCG: epigallocatechin-3-gallate topical serum.</p></fn></table-wrap-foot></table-wrap></floats-group></article>